var title_f39_9_40080="HP infiltrate Light";
var content_f39_9_40080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows an intense interstitial lymphoplasmacytic infiltrate in a peribronchiolar pattern. Small accumulations of epithelioid histiocytes may be present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40080=[""].join("\n");
var outline_f39_9_40080=null;
var title_f39_9_40081="Epidermolysis bullosa acquisita split skin immunofluorescence";
var content_f39_9_40081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Serum IgG basement membrane zone antibodies localizing to the dermal side of split skin substrate in epidermolysis bullosa acquisita by indirect immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear IgG antibody staining on the dermal side of basement membrane zone-split skin substrate characteristic of epidermolysis bullosa acquisita. This pattern also is referred to as staining the floor of the blister.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40081=[""].join("\n");
var outline_f39_9_40081=null;
var title_f39_9_40082="Ethanolamine oleate: Drug information";
var content_f39_9_40082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethanolamine oleate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ethamolin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Sclerosing Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Esophageal varices (sclerotherapy): Injection: 1.5-5 mL per varix, up to 20 mL total or 0.4 mL/kg for a 50 kg patient; doses should be decreased in patients with severe hepatic dysfunction and should receive less than recommended maximum dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F168119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethamolin&reg;: 5% (2 mL) [contains benzyl alcohol; 50 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use care to use acceptable technique to avoid necrosis",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Orphan drug:",
"     </b>",
"     Sclerosing agent used for bleeding esophageal varices",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ethamolin&reg; may be confused with ethanol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pyrexia (1.8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Esophageal ulcer (2%), esophageal stricture (1.3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pleural effusion (2%), pneumonia (1.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Retrosternal pain (1.6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, anaphylaxis, esophagitis, injection necrosis, perforation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to agent or oleic acid",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Fatal anaphylactic shock has been reported following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspiration pneumonia: Fatal aspiration pneumonia has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiorespiratory disease: Use with caution in patients with concomitant cardiorespiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with significant liver dysfunction (Child class C); decreased dose recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Critically-ill patients: Use with caution in critically-ill patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13801060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ethamolin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (2 mL): $96.19",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Derived from oleic acid and similar in physical properties to sodium morrhuate; however, the exact mechanism of the hemostatic effect used in endoscopic injection sclerotherapy is not known. Intravenously injected ethanolamine oleate produces a sterile inflammatory response resulting in fibrosis and occlusion of the vein; a dose-related extravascular inflammatory reaction occurs when the drug diffuses through the venous wall. Autopsy results indicate that variceal obliteration occurs secondary to mural necrosis and fibrosis. Thrombosis appears to be a transient reaction.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9431 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40082=[""].join("\n");
var outline_f39_9_40082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168117\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168124\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168118\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168119\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881389\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881390\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168111\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168099\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168113\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168112\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168130\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168122\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168115\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168103\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299291\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168108\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168109\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801059\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801060\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323136\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168102\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40083="Ioflupane I-123: Patient drug information";
var content_f39_9_40083=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ioflupane I-123: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/4/21572?source=see_link\">",
"     see \"Ioflupane I-123: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13374859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DaTscan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13385600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a brain scan.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13385599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ioflupane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13385603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13385604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13385605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13385602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13385606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13385607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17073 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40083=[""].join("\n");
var outline_f39_9_40083=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374859\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385600\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385599\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385603\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385604\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385605\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385602\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385606\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385607\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/4/21572?source=related_link\">",
"      Ioflupane I-123: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40084="Differential diagnosis of infection following renal transplantation";
var content_f39_9_40084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of infection following renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40084/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40084/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40084/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40084/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40084/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40084/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/9/40084/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are the leading cause of morbidity and mortality in the early posttransplant period, as more than 80 percent of recipients suffer at least one episode of infection in the first year. Infection and allograft dysfunction caused by rejection are closely interrelated through the use of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1\">",
"     1",
"    </a>",
"    ]. The level of overall immunosuppression used for induction therapy, maintenance therapy, and the treatment of acute rejection episodes is the major risk factor for posttransplant infection, rather than the use of a specific immunosuppressive agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patterns of opportunistic infections after transplantation have been altered by routine antimicrobial prophylaxis for Pneumocystis carinii (also called P. jirovecii) and cytomegalovirus. These patterns are changing due to the emergence of new clinical syndromes (such as polyoma virus allograft nephropathy) and by infections due to organisms with antimicrobial resistance. New quantitative molecular and antigen-based microbiologic assays detect previously unrecognized transplantation-associated pathogens such as lymphocytic choriomeningitis virus. These assays are used in the management of common infections such as those due to cytomegalovirus and Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of infection is influenced by a variety of other factors including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental exposure to an infecting agent, reactivation of a previously latent infection, or (rarely) active infection transmitted with the allograft.",
"     </li>",
"     <li>",
"      Presence of indwelling catheters.",
"     </li>",
"     <li>",
"      Nutritional status and metabolic factors such as uremia and uncontrolled hyperglycemia.",
"     </li>",
"     <li>",
"      Infection with immunomodulating viruses such as cytomegalovirus, Epstein-Barr virus, hepatitis B and C virus, and HIV.",
"     </li>",
"     <li>",
"      Type of dialysis modality utilized prior to transplantation. Peritoneal dialysis is associated with a significantly higher risk of infectious complications after surgery compared with hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The occurrence of certain types of infections, as well as the organisms involved, tend to follow a general temporal pattern in the posttransplant period (",
"    <a class=\"graphic graphic_figure graphicRef58770 \" href=\"mobipreview.htm?21/33/22035\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/6\">",
"     6",
"    </a>",
"    ]. It is unclear whether the introduction of newer immunosuppressive agents will alter these temporal associations.",
"   </p>",
"   <p>",
"    It is therefore useful to approach the differential diagnosis of posttransplant infection according to the time of occurrence after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The remainder of this topic will review the approach to posttransplant infection; specific infections are discussed separately (see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY POSTTRANSPLANT INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first month after transplantation, the usual postoperative surgical infections, similar to those seen in nonimmunosuppressed patients undergoing similar surgical procedures, are most common. Examples include bacterial or fungal organisms causing wound infection, bacterial pneumonia, and bacterial or fungal infections related to urinary or peritoneal dialysis catheters, or central venous lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Occasionally, bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal organisms are transmitted by a contaminated allograft, although donors are usually carefully screened for presence of contaminating organisms.",
"   </p>",
"   <p>",
"    Opportunistic infections, such as those due to Pneumocystis carinii and Nocardia asteroides, are rare in this time period, even though the patient is exposed to the highest degree of immunosuppression both to prevent and, in some cases, to treat acute rejection. This observation indicates that the duration of exposure to immunosuppression is an important determinant of the risk for opportunistic infection following transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ONE TO SIX MONTHS AFTER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the period from one to six months after transplantation, infections with immunomodulating viruses, particularly cytomegalovirus, are most important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .) In addition to the clinical syndromes induced by these viruses, their immunomodulating properties predispose to opportunistic infections with such organisms as Pneumocystis jiroveci pneumonia (previously known as P. carinii), Listeria monocytogenes, and Aspergillus fumigatus.",
"   </p>",
"   <p>",
"    Other infections commonly occurring during this period include hepatitis, Herpes simplex, Herpes zoster, Mycobacterium tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/10\">",
"     10",
"    </a>",
"    ], Epstein-Barr virus (EBV), which can be complicated by the development of lymphoproliferative disorders, and recurrence or relapse of urinary tract infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20579?source=see_link\">",
"     \"Urinary tract infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LATE POSTTRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients in the late posttransplant period (more than six months after transplantation) have stable allograft function and are maintained on minimal immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .) Infection in the majority of these patients is usually similar to that seen in the general population (influenza, pneumococcal pneumonia, benign urinary tract infections, etc). However, approximately 10 to 15 percent of patients have chronic viral infections that become clinically evident at this time. Examples include CMV chorioretinitis, lymphoproliferative disorders due to EBV, chronic hepatitis, and clinical AIDS.",
"   </p>",
"   <p>",
"    A small number of patients (five to 15 percent) have a history of multiple acute rejection episodes and high degrees of immunosuppression. These patients are at risk for serious opportunistic infections with significant morbidity and mortality. Examples include those caused by Pneumocystis carinii, Listeria monocytogenes, and Nocardia asteroides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the recommendations we follow for routine antimicrobial prophylaxis of renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioperative surgical antibiotic prophylaxis with broad spectrum antibiotics (which varies from center to center) for prevention of wound infections.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      is given for the prevention of urinary tract infection, sepsis, and Pneumocystis jiroveci pneumonia and Nocardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1,11,12\">",
"       1,11,12",
"      </a>",
"      ]. In one study, for example, 132 patients were randomized to receive trimethoprim-sulfamethoxazole or placebo after renal transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/12\">",
"       12",
"      </a>",
"      ]. Active therapy was associated with marked reductions in the incidence of urinary tract infection after removal of the bladder catheter (nine versus 36 in the placebo group), gram negative enteric infections (four versus 46), and bacteremia or fungemia (one versus nine).The dose of trimethoprim-sulfamethoxazole should be adjusted according to renal function. The usual dose is one double strength tablet daily if the plasma creatinine concentration is less than 2 to 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (176 to 264",
"      <span class=\"nowrap\">",
"       &micro;mol/L),",
"      </span>",
"      and one double strength tablet every other day or one single strength tablet daily if the plasma creatinine concentration is greater than 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;264",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      Lower doses offer less protection against bacterial infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/12\">",
"       12",
"      </a>",
"      ]. We usually continue prophylactic therapy for one year in patients with normal urinary tracts. However, indefinite therapy is indicated in patients with a history of recurrent urinary tract infections, anatomic urinary tract abnormalities, or a neurogenic bladder. Patients who are allergic to trimethoprim-sulfamethoxazole can be treated with any of the oral quinolones, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      to prevent urinary tract infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1,13\">",
"       1,13",
"      </a>",
"      ]. Such patients should also receive effective prophylaxis against Pneumocystis with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      1500 mg daily or monthly nebulized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      300 mg. The use of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      to prevent Pneumocystis is generally not recommended, as there is an increased incidence of hemolytic anemia in transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40084/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMV prophylaxis is essential in several clinical settings. The aim is to prevent primary infection in CMV-negative recipients of CMV-positive donors and to prevent reactivation of infection in some CMV-positive recipients, particularly those receiving antirejection therapy with OKT3. The specific regimens that are used are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122108439\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious complications are common within the first year after transplantation. It is important to realize that the clinical manifestations of infection in the compromised host are variable and often atypical. The differential diagnosis should be considered according to the timeline. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the first month after transplantation, the usual postoperative surgical infections, similar to those seen in nonimmunosuppressed patients undergoing similar surgical procedures, are most common. Examples include bacterial or fungal organisms causing wound infection, bacterial pneumonia, and bacterial or fungal infections related to urinary or peritoneal dialysis catheters, or central venous lines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early posttransplant infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the period from one to six months after transplantation, infections with immunomodulating viruses, particularly cytomegalovirus, are most important. In addition to the clinical syndromes induced by these viruses, their immunomodulating properties predispose to opportunistic infections with such organisms as Pneumocystis jiroveci pneumonia (previously known as P. carinii), Listeria monocytogenes, and Aspergillus fumigatus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'One to six months after transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients in the late posttransplant period (more than six months after transplantation) have stable allograft function and are maintained on minimal immunosuppressive therapy. Infection in the majority of these patients is usually similar to that seen in the general population (influenza, pneumococcal pneumonia, benign urinary tract infections, etc). However, approximately 10 to 15 percent of patients have chronic viral infections that become clinically evident at this time. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Late posttransplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of antimicrobial agents are routinely administered to kidney transplant recipients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antimicrobial prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/1\">",
"      Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/2\">",
"      Jamil B, Nicholls K, Becker GJ, Walker RG. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/3\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/4\">",
"      Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/5\">",
"      Passalacqua JA, Wiland AM, Fink JC, et al. Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Transplantation 1999; 68:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/6\">",
"      Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 1981; 70:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/7\">",
"      Bakir N, Surachno S, Sluiter WJ, Struijk DG. Peritonitis in peritoneal dialysis patients after renal transplantation. Nephrol Dial Transplant 1998; 13:3178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/8\">",
"      Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation 2002; 74:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/9\">",
"      Kamath NS, John GT, Neelakantan N, et al. Acute graft pyelonephritis following renal transplantation. Transpl Infect Dis 2006; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/10\">",
"      Torre-Cisneros J, Cast&oacute;n JJ, Moreno J, et al. Tuberculosis in the transplant candidate: importance of early diagnosis and treatment. Transplantation 2004; 77:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/11\">",
"      Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis 1982; 4:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/12\">",
"      Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990; 89:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/13\">",
"      Hernandez Poblete G, Morales JM, Prieto C, et al. Usefulness of norfloxacine prophylaxis in late recurrent urinary tract infection after renal transplantation. Nephron 1990; 54:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40084/abstract/14\">",
"      Lee I, Barton TD, Goral S, et al. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant 2005; 5:2791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7306 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40084=[""].join("\n");
var outline_f39_9_40084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H122108439\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY POSTTRANSPLANT INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ONE TO SIX MONTHS AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LATE POSTTRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTIMICROBIAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H122108439\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/33/22035\" title=\"figure 1\">",
"      Infection timeline SOT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20579?source=related_link\">",
"      Urinary tract infection in renal transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40085="Verrucous sarcoidosis";
var content_f39_9_40085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verrucous sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Verrucous sarcoidosis consisting of discrete hyperkeratotic, thick, hyperpigmented plaques. These types of lesions may be misdiagnosed as lichenified psoriasis, prurigo nodularis, or hypertrophic lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40085=[""].join("\n");
var outline_f39_9_40085=null;
var title_f39_9_40086="Pentostatin: Drug information";
var content_f39_9_40086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentostatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/41/16021?source=see_link\">",
"    see \"Pentostatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/60/24518?source=see_link\">",
"    see \"Pentostatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nipent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nipent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antibiotic;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Purine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hairy cell leukemia:",
"     </b>",
"     I.V.: 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CLL (unlabeled use):",
"     </b>",
"     I.V.: 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 3 weeks, then every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous T-cell lymphoma (unlabeled use):",
"     </b>",
"     I.V.: 3.75-5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     daily for 3 days every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute GVHD (unlabeled use):",
"     </b>",
"     I.V.: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     daily for 3 days; may repeat after 2 weeks if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic GVHD (unlabeled use):",
"     </b>",
"     I.V.: 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks for 12 doses; then 4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3-4 weeks (if still improving)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F182958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain renal dosage adjustment guidelines; use with caution in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute. Two patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-60 mL/minute achieved responses when treated with 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 70% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 60% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Consider use of alternative drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lathia, 2002:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nipent&reg;: 10 mg [contains mannitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F182938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. 20- to 30-minute infusion or I.V. bolus over 5 minutes. Hydrate with 500-1000 mL fluid prior to infusion and 500 mL after infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fludarabine, melphalan, ondansetron, paclitaxel, sargramostim.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hairy cell leukemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5517180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous T-cell lymphoma, chronic lymphocytic leukemia (CLL), and acute and chronic graft-versus-host-disease (GVHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentostatin may be confused with pentamidine, pentosan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nipent [U.S., Canada, and multiple international markets] may be confused with Nipin brand name for nifedipine [Italy, Singapore]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (42% to 46%), fatigue (29% to 42%), pain (8% to 20%), chills (11% to 19%), headache (13% to 17%), CNS toxicity (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (26% to 43%), pruritus (10% to 21%), skin disorder (4% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (22% to 63%), diarrhea (15% to 17%), anorexia (13% to 16%), abdominal pain (4% to 16%), stomatitis (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (nadir: 7 days; recovery: 10-14 days), leukopenia (22% to 60%), anemia (8% to 35%), thrombocytopenia (6% to 32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (11% to 19%), weakness (10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (17% to 20%), upper respiratory infection (13% to 16%), rhinitis (10% to 11%), dyspnea (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (7% to 36%), allergic reaction (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3% to 10%), facial edema (3% to 10%), hypotension (3% to 10%),  peripheral edema (3% to 10%), angina (&lt;3%), arrhythmia (&lt;3%), AV block (&lt;3%), bradycardia (&lt;3%), cardiac arrest (&lt;3%), deep thrombophlebitis (&lt;3%), heart failure (&lt;3%), hypertension (&lt;3%), pericardial effusion (&lt;3%), sinus arrest (&lt;3%), syncope (&lt;3%), tachycardia (&lt;3%), vasculitis (&lt;3%), ventricular extrasystoles (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety (3% to 10%), confusion (3% to 10%), depression (3% to 10%), dizziness (3% to 10%), insomnia (3% to 10%), nervousness (3% to 10%), somnolence (3% to 10%), abnormal dreams/thinking (&lt;3%), amnesia (&lt;3%), ataxia (&lt;3%), emotional lability (&lt;3%), encephalitis (&lt;3%), hallucination (&lt;3%), hostility (&lt;3%), meningism (&lt;3%), neuritis (&lt;3%), neurosis (&lt;3%), seizure (&lt;3%), vertigo (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cellulitis (6%), furunculosis (4%), dry skin (3% to 10%), urticaria (3% to 10%), acne (&lt;3%), alopecia (&lt;3%), eczema (&lt;3%), petechial rash (&lt;3%), photosensitivity (&lt;3%), abscess (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (&lt;3%), hypercalcemia (&lt;3%), hyponatremia (&lt;3%), gout (&lt;3%), libido decreased/loss (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (3% to 10%) flatulence (3% to 10%), gingivitis (3% to 10%), constipation (&lt;3%), dysphagia (&lt;3%), glossitis (&lt;3%), ileus (&lt;3%), taste perversion (&lt;3%), oral moniliasis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%), impotence (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (3% to 10%), hemorrhage (3% to 10%), acute leukemia (&lt;3%), aplastic anemia (&lt;3%), hemolytic anemia (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (3% to 10%), paresthesia (3% to 10%), arthritis (&lt;3%), dysarthria (&lt;3%), hyperkinesia (&lt;3%), neuralgia (&lt;3%), neuropathy (&lt;3%), paralysis (&lt;3%), twitching (&lt;3%), osteomyelitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (4%), amblyopia (&lt;3%), eyes nonreactive (&lt;3%), lacrimation disorder (&lt;3%), photophobia (&lt;3%), retinopathy (&lt;3%), vision abnormal (&lt;3%), watery eyes (&lt;3%), xerophthalmia (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness (&lt;3%), earache (&lt;3%), labyrinthitis (&lt;3%), tinnitus (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (3% to 10%), nephropathy (&lt;3%), renal failure (&lt;3%), renal insufficiency (&lt;3%), renal function abnormal (&lt;3%), renal stone (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (8% to 10%), sinusitis (6%), pneumonia (5%), asthma (3% to 10%), bronchitis (3%), bronchospasm (&lt;3%), laryngeal edema (&lt;3%), pulmonary embolus (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (8% to 10%), herpes zoster (8%), viral infection (&le;8%), bacterial infection (5%), herpes simplex (4%), sepsis (3%), flu-like syndrome (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dysuria, fungal infection (skin), hematuria, lethargy, pulmonary edema, pulmonary toxicity (fatal; in combination with fludarabine), uveitis/vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentostatin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May occur, primarily early in treatment; if neutropenia persists beyond early cycles, evaluate for disease status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity:",
"     <b>",
"      [U.S. Boxed Warnings]: Severe CNS toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.",
"     </b>",
"     Withhold treatment for CNS toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warnings]: Severe liver toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.",
"     </b>",
"     May cause elevations (reversible) in liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity:",
"     <b>",
"      [U.S. Boxed Warnings]: Severe pulmonary toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.  Do not administer concurrently with fludarabine; concomitant use has resulted in serious or fatal pulmonary toxicity.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: Severe rashes may occur and worsen with therapy continuation; may require withholding of treatment or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity:",
"     <b>",
"      [U.S. Boxed Warnings]: Severe renal toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: In patients who present with infections prior to treatment, infections should be resolved, if possible, prior to initiation of treatment. Treatment should be temporarily withheld for active infections during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute); the terminal half-life is prolonged; appropriate dosing guidelines in renal insufficiency have not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carmustine/etoposide/cyclophosphamide: Fatal pulmonary edema and hypotension have been reported in patients treated with pentostatin in combination with carmustine, etoposide, or high-dose cyclophosphamide as part of a myeloablative regimen for bone marrow transplant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: Pentostatin may enhance the cardiotoxic effect of Cyclophosphamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fludarabine: May enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelarabine: Pentostatin may diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegademase Bovine: May diminish the therapeutic effect of Pentostatin. Pentostatin may diminish the therapeutic effect of Pegademase Bovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenicity, maternal toxicity, and fetal loss. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5517182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in nursing the infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Nipent Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $2016.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Pentostatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $2280.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5517303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, liver function, serum uric acid, renal function (creatinine clearance), bone marrow evaluation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nipent (BE, DE, ES, FR, GB, GR, IT, KP, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentostatin is a purine antimetabolite that inhibits adenosine deaminase, preventing the deamination of adenosine to inosine. Accumulation of deoxyadenosine (dAdo) and deoxyadenosine 5&prime;-triphosphate (dATP) results in a reduction of purine metabolism and DNA synthesis and cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      d",
"     </sub>",
"     : 36.1 L (20.1 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ); rapidly to body tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution half-life: 11-85 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 3-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute): 4-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% to 96%) within 24 hours (30% to 90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      al-Razzak LA, Benedetti AE, Waugh WN, et al, &ldquo;Chemical Stability of Pentostatin (NSC-218321), a Cytotoxic and Immunosuppressant Agent,&rdquo;",
"      <i>",
"       Pharm Res",
"      </i>",
"      , 1990, 7(5):452-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/2367313/pubmed\" id=\"2367313\" target=\"_blank\">",
"        2367313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bolanos-Meade J, Jacobsohn DA, Margolis J, et al, &ldquo;Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(12):2661-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/15837980/pubmed\" id=\"15837980\" target=\"_blank\">",
"        15837980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN and Sorkin EM, &ldquo;Pentostatin. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Lymphoproliferative Disorders,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(4):652-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/7506651/pubmed\" id=\"7506651\" target=\"_blank\">",
"        7506651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catovsky D, &ldquo;Clinical Experience With 2&prime;-Deoxycoformycin,&rdquo;",
"      <i>",
"       Hematol Cell Ther",
"      </i>",
"      , 1996, 38(Suppl 2):103-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dillman RO, &ldquo;A New Chemotherapeutic Agent: Deoxycoformycin (Pentostatin),&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1994, 31(1):16-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dillman RO, Mick R and McIntyre OR, &ldquo;Pentostatin in Chronic Lymphocytic Leukemia: A Phase II Trial of Cancer and Leukemia Group B,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(4):433-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/2784491/pubmed\" id=\"2784491\" target=\"_blank\">",
"        2784491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grever MR, Siaw MFE, Jacob WF, et al, &ldquo;The Biochemical and Clinical Consequences of 2'-Deoxycoformycin in Refractory Lymphoproliferative Malignancy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1981, 57(3):406-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/6970050/pubmed\" id=\"6970050\" target=\"_blank\">",
"        6970050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsohn DA, Chen AR, Zahurak M, et al, &ldquo;Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(27):4255-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/17878478/pubmed\" id=\"17878478\" target=\"_blank\">",
"        17878478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane BJ, Kuhn JG, and Roush MK, &ldquo;Pentostatin: An Adenosine Deaminase Inhibitor For the Treatment of Hairy Cell Leukemia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(7-8):939-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/1504408/pubmed\" id=\"1504408\" target=\"_blank\">",
"        1504408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurzrock R, Pilat S, and Duvic M, &ldquo;Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(10):3117-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/10506607/pubmed\" id=\"10506607\" target=\"_blank\">",
"        10506607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lathia C, Fleming GF, Meyer M, et al, &ldquo;Pentostatin Pharmacokinetics and Dosing Recommendations in Patients With Mild Renal Impairment,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2002, 50(2):121-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/12172976/pubmed\" id=\"12172976\" target=\"_blank\">",
"        12172976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Margolis J and Grever MR, \"Pentostatin (Nipent): A Review of Potential Toxicity and its Management,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2000, 27(2 Suppl 5):9-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tsimberidou AM, Giles F, Duvic M, et al, &ldquo;Phase II Study of Pentostatin in Advanced T-Cell Lymphoid Malignancies: Update of an M.D. Anderson Cancer Center Series,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(2):342-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/9/40086/abstract-text/14716770/pubmed\" id=\"14716770\" target=\"_blank\">",
"        14716770",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9756 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40086=[""].join("\n");
var outline_f39_9_40086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709202\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182953\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182954\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182981\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182956\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182957\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182958\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182935\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182921\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182938\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182986\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182936\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5517180\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182988\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182979\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182941\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182925\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299851\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182930\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182932\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182943\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182965\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5517182\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323197\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5517303\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182944\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182924\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182940\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9756|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/41/16021?source=related_link\">",
"      Pentostatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/60/24518?source=related_link\">",
"      Pentostatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40087="Milk allergy: Management";
var content_f39_9_40087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Milk allergy: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40087/contributors\">",
"     Kirsi M Jarvinen-Seppo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40087/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40087/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/9/40087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk allergy (CMA) is the most common food allergy in young children, but is uncommon in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/1\">",
"     1",
"    </a>",
"    ]. This food allergy presents with a wide range of clinical syndromes due to immunologic responses to cow's milk proteins that can be immunoglobulin (Ig)E-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-IgE-mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] CMA does not include other adverse reactions to milk, such as lactose intolerance, which are non-immune mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues of cross-reactivity among milk of different mammalian species (such as sheep and goat) are addressed here. This topic also reviews various aspects of management of milk allergy, including instructions about avoidance of milk protein, replacement of milk with alternative protein and calcium sources, education in the proper management of accidental exposures, and monitoring for resolution of the allergy. The epidemiology, pathogenesis, clinical features, and diagnosis of milk allergy are discussed separately. General discussions of food allergy are presented separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=see_link\">",
"     \"Milk allergy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CROSS-REACTIVITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Allergy to other mammalian milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CMA do not tolerate milk from sheep and goats, and they are unlikely to tolerate milk from deer, ibex, and buffalo as well. However, some patients with CMA may tolerate milk from other mammals, such as camels, pigs, reindeer, horses, and donkeys.",
"   </p>",
"   <p>",
"    Mammals that are phylogenetically related, such as cow and water buffalo, sheep and goat, and horse and donkey, have similar milk protein expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/6\">",
"     6",
"    </a>",
"    ]. In vitro studies have shown extensive cross-reactivity between milk from cows, sheep, and goats, but only weak cross-reactivity with proteins from donkeys and mares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/7\">",
"     7",
"    </a>",
"    ]. Significant amino acid sequence homology and resulting high rate of clinical cross-reactivity between milk from ruminants (eg, approximately 90 percent of children with IgE-mediated CMA react to goat's milk) makes milk from sheep and goats inappropriate feeding alternatives for most cow's milk-allergic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, some patients with primary goat's or sheep's milk allergy may tolerate cow's milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cosensitization, assessed by skin testing, to deer's, ibex' (wild mountain goat) and buffalo's milk is common in patients with CMA, but positive skin tests to camel's and pig's milk are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/12\">",
"     12",
"    </a>",
"    ]. There is also only partial cross-reactivity between cow's milk and reindeer's milk beta-lactoglobulins in patients with CMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/13\">",
"     13",
"    </a>",
"    ]. However, studies on clinical tolerability of these alternative mammalian milks are missing.",
"   </p>",
"   <p>",
"    Clinical studies on allergenicity of equine milk (mare's and donkey's milk) suggest it may be tolerated by most children with CMA, with the possible exception of those individuals who have a history of anaphylaxis to milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/7,9,14-17\">",
"     7,9,14-17",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, crossover study showed that donkey's milk was better tolerated and more effective than goat's milk in reducing symptoms of atopic dermatitis in children with CMA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/9\">",
"       9",
"      </a>",
"      ]. Nearly 90 percent",
"      <span class=\"nowrap\">",
"       (23/26)",
"      </span>",
"      of these children reacted to goat's milk when challenged, but only one reacted to donkey's milk.",
"     </li>",
"     <li>",
"      Similar findings were seen in two prospective studies of selected children with CMA. In the first study, 83 percent",
"      <span class=\"nowrap\">",
"       (38/46)",
"      </span>",
"      of children tolerated heated donkey's milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/15\">",
"       15",
"      </a>",
"      ]. In the second study, 96 percent",
"      <span class=\"nowrap\">",
"       (24/25)",
"      </span>",
"      of children tolerated fresh donkey's milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, 80 percent of children with prior anaphylaxis to cow's milk reacted to donkey's milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Human milk does not contain beta-lactoglobulin, unlike other mammalian milks. However, there is significant amino acid sequence homology between other bovine and human milk proteins, suggesting that cross-reactivity between conserved regions of bovine and human casein may exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Clinical allergy to human milk was shown in one case report and sensitization to human milk was reported in two studies, although confirmatory clinical data are missing and the clinical significance is largely unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cross-reactivity to other protein sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Co-sensitization (by skin testing) to soy is common in patients with CMA, but clinical co-allergy due to cross-sensitization based upon cross-reactive proteins between soy and milk is not. In one study, co-sensitization to soy milk was noted in 17 percent of patients with CMA, but all of these patients tolerated ingestion of soy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/12\">",
"     12",
"    </a>",
"    ]. Another small study reported a 10 percent incidence of clinical soy allergy, mostly non-IgE-mediated, in infants with CMA fed soy formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/23\">",
"     23",
"    </a>",
"    ]. These limited data suggest that soy is a safe alternative for many children with CMA, especially those with IgE-mediated CMA.",
"   </p>",
"   <p>",
"    Serum albumin is found in both milk and meat. This protein is thought to be involved in cosensitization to milk and beef, reported in 13 to 20 percent of children with CMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/24\">",
"     24",
"    </a>",
"    ]. Clinical cross-reactivity may be more pronounced with less well-cooked meat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/25\">",
"     25",
"    </a>",
"    ]. In another study, seven of eight patients with persistent CMA who were sensitized to cow's milk, bovine serum albumin, and animal dander recognized serum albumin in different raw, but not heated, meats (beef, lamb, deer, and pork), and epithelia (dog, cat, and cow) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link&amp;anchor=H3#H3\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Cow's milk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link&amp;anchor=H15#H15\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Meats'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of milk allergy does not differ from that of other food allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/27\">",
"     27",
"    </a>",
"    ]. It requires instructions on avoidance and education about treatment of reactions in the event of accidental exposure. It also includes monitoring for the resolution of the allergy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of food allergy in the specific settings of schools and camps is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=see_link\">",
"     \"Food allergy in schools and camps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most straightforward approach in managing any food allergy is complete avoidance of the culprit food. Eliminating milk from the diet can be difficult and can pose nutritional as well as quality of life concerns, since milk is a ubiquitous food and is an important source of fat and protein in early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/28\">",
"     28",
"    </a>",
"    ]. Milk is or may be an ingredient in baked goods, cereals, chocolate, candy, custard, pudding, sherbet, luncheon meats, hot dogs, sausages, margarine, salad dressing, breaded foods, casseroles, soups, and potato, pasta, and vegetable dishes (",
"    <a class=\"graphic graphic_table graphicRef63271 \" href=\"mobipreview.htm?37/5/37980\">",
"     table 1",
"    </a>",
"    ). It may also be found in some milk, cream, and butter substitutes, even those labeled \"non-dairy\". Accidental exposures are common. In one prospective series of 500 infants aged 3 to 15 months with suspected or confirmed egg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    milk allergy, 72 percent had an allergic reaction, most commonly to milk, egg, or peanut, during a three-year period, with an annualized reaction rate of 0.81 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/29\">",
"     29",
"    </a>",
"    ]. Eighty-seven percent of these reactions were due to accidental exposures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7993?source=see_link\">",
"     \"Nutritional issues in food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42759?source=see_link\">",
"     \"Food allergy: Impact on health-related quality of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link&amp;anchor=H7#H7\">",
"     \"The natural history of childhood food allergy\", section on 'Role of avoidance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Counseling about avoidance should include discussions about the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cross-contact and hidden ingredients &mdash; Patients must be counseled about accidental exposure to food allergens via cross-contact (ie, inadvertent exposure to the allergenic food by contamination of 'safe' foods with small amounts of the culprit food). This can happen anywhere food is served, including at restaurants using knives and counters contaminated with dairy product and on shared grills. In addition, breads and pastries may be brushed with milk.",
"     </li>",
"     <li>",
"      Food labels &mdash; Patients must read all food labels (",
"      <a class=\"graphic graphic_table graphicRef63271 \" href=\"mobipreview.htm?37/5/37980\">",
"       table 1",
"      </a>",
"      ). Legislation has been enacted in the United States mandating that ingredient labels on food packages plainly identify the presence of eight specified allergenic foods, including milk (as well as egg, tree nuts, peanuts, wheat, soybeans, fish and Crustacean shellfish). Other countries are addressing issues of food labeling as well. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of food allergy: Avoidance\", section on 'Food labeling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advisory labeling &mdash; Some products in the United States may have advisory labeling, such as \"may contain milk\". This type of labeling is not currently regulated. The risk of allergic reactions to these products is not known, and the frequency and amount of milk contamination in these products is high, particularly for dark chocolate products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of food allergy: Avoidance\", section on 'Advisory labeling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extensively heated milk &mdash; Many individuals with CMA can tolerate extensively heated or baked forms of milk. However, the only available diagnostic test to determine which individuals can tolerate extensively heated milk (unless it is currently in their diet) is an oral food challenge. Data suggest that tolerance to extensively heated milk is a good prognostic factor for the development of tolerance to less heated forms of milk and that including extensively heated milk in the diet may accelerate the development of tolerance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link&amp;anchor=H7#H7\">",
"       \"The natural history of childhood food allergy\", section on 'Role of avoidance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dairy substitutes &mdash; Counseling should include a discussion about",
"      <span class=\"nowrap\">",
"       milk/dairy",
"      </span>",
"      alternatives and substitutes (",
"      <a class=\"graphic graphic_table graphicRef55081 \" href=\"mobipreview.htm?29/52/30539\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79377 \" href=\"mobipreview.htm?9/53/10075\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74819 \" href=\"mobipreview.htm?17/16/17676\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63667 \" href=\"mobipreview.htm?0/36/587\">",
"       table 5",
"      </a>",
"      ). Commercial products marketed as \"non-dairy\" or as",
"      <span class=\"nowrap\">",
"       milk/dairy",
"      </span>",
"      substitutes or alternatives may have milk ingredients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Allergy to other mammalian milk'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7993?source=see_link&amp;anchor=H11#H11\">",
"       \"Nutritional issues in food allergy\", section on 'Cow's milk allergy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unexpected and non-food sources &mdash; Medications, various health foods, and cosmetics may have ingredients derived from milk. Labeling of non-food items is not strictly regulated in the United States. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of food allergy: Avoidance\", section on 'Food allergens in non-food items'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk is an essential fat and protein source, especially for infants and toddlers. Thus, alternative milk sources are necessary (",
"    <a class=\"graphic graphic_table graphicRef79377 \" href=\"mobipreview.htm?9/53/10075\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55081 \" href=\"mobipreview.htm?29/52/30539\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74819 \" href=\"mobipreview.htm?17/16/17676\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63667 \" href=\"mobipreview.htm?0/36/587\">",
"     table 5",
"    </a>",
"    ). Alternative milk beverages are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7993?source=see_link&amp;anchor=H11#H11\">",
"     \"Nutritional issues in food allergy\", section on 'Cow's milk allergy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Allergy to other mammalian milk'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical scenarios",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following scenarios illustrate some of the issues involved and our management approach. Individual clinicians may decide to adopt different strategies depending upon their level of expertise and the resources available (eg, ability to perform oral food challenges).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a patient with an allergy to milk in any or all forms or of any severity wishes to avoid all milk-containing foods, we do not discourage this approach.",
"     </li>",
"     <li>",
"      We allow persons with IgE-mediated allergy to continue to eat milk in more processed forms than what triggered their reaction(s) if they have eaten milk in these forms regularly and in the recent past (similar to passing an oral food challenge). In most cases this involves patients who reacted to straight milk or lightly processed forms of milk (eg, ice cream, cheese), but have a history of tolerating extensively heated milk (eg, milk in baked goods). We generally suggest that these patients avoid more intermediate forms of cooked or processed milk, such as pudding, yogurt, casseroles, and milk chocolate. In contrast, we generally recommend that patients with mixed or non-IgE mediated allergy, such as eosinophilic esophagitis, avoid milk protein in all forms.",
"      <br/>",
"      <br/>",
"      One caveat to this approach that should be discussed with patients is that it is possible that a patient may have a reaction due to ingestion of a larger amount of milk or a more lightly cooked or processed form of milk than usual (eg, normally tolerates milk in pancakes, but has a reaction when blueberries are used in the pancakes and the batter does not cook completely around the blueberries).",
"     </li>",
"     <li>",
"      We recommend that patients who have reacted to intermediately",
"      <span class=\"nowrap\">",
"       cooked/processed",
"      </span>",
"      or extensively heated milk avoid all forms of milk.",
"     </li>",
"     <li>",
"      An oral challenge to extensively heated milk may be performed by an allergy specialist if a patient is not currently eating milk in this form, but the patient (or parents of the patient) wishes to introduce it into the diet. Caution is needed, because severe reactions can occur from this type of oral food challenge. In addition, the impact of ingesting heated milk on the course of the allergy is not yet understood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of reactions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acute IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of individuals with IgE-mediated milk allergy is important, because these patients are at risk for severe reactions (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64957 \" href=\"mobipreview.htm?35/20/36172\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. As in other forms of food allergy, the severity of symptoms in a given individual with milk allergy may vary considerably between reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, the severity of an initial reaction does not predict the patient's subsequent risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four of eight cases of fatal food-induced anaphylaxis reported over a ten year period in the United Kingdom were caused by milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/34\">",
"       34",
"      </a>",
"      ], and four of 31 cases reported over a five year period in the United States were due to milk allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small study investigating whether children with milk allergy of varying severity could tolerate extensively heated forms of milk, 35 percent of children who reacted to extensively heated milk required treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of children who underwent oral food challenges for evaluation of food allergy and failed challenges to milk, 37 percent had moderate reactions and 27 percent had severe reactions on challenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children whose only apparent clinical manifestation of food allergy is atopic dermatitis are at risk of an acute systemic reaction upon reintroduction of that food after an elimination diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40087/abstract/38-41\">",
"       38-41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, we recommend that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors be prescribed for all patients with a history of anaphylactic reactions to milk. We suggest that epinephrine autoinjectors be prescribed for all patients with milder IgE-mediated reactions to milk. In addition, the patient should have a written anaphylaxis emergency action plan (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ). These measures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Delayed gastrointestinal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with food protein-induced enterocolitis and patients with eosinophilic esophagitis is presented in the specific topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Monitoring for resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with milk allergy should be monitored for resolution of the allergy, since most will outgrow the allergy in childhood. The steps to take to determine if an allergy has resolved are covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=see_link&amp;anchor=H18#H18\">",
"     \"Milk allergy: Clinical features and diagnosis\", section on 'Natural course'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link&amp;anchor=H8#H8\">",
"     \"The natural history of childhood food allergy\", section on 'Monitoring the food-allergic child'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link&amp;anchor=H16#H16\">",
"     \"The natural history of childhood food allergy\", section on 'Natural history of specific allergies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management of younger siblings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents often inquire about what measures to take to prevent milk allergy (eg, maternal avoidance during pregnancy and lactation) and when to introduce milk and milk-containing products in a younger sibling of a child with milk allergy. In these cases, avoidance of milk is not recommended for nursing mothers. Hydrolyzed formula is recommended for formula-fed infants or for supplementation for breast-fed infants (",
"    <a class=\"graphic graphic_table graphicRef79377 \" href=\"mobipreview.htm?9/53/10075\">",
"     table 3",
"    </a>",
"    ). Delayed introduction of milk-containing products beyond six months of age is not recommended, unless the infant is showing signs of allergic disease (straight milk is delayed until one year of age for other reasons). These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link&amp;anchor=H38#H38\">",
"     \"Pathogenesis of food allergy\", section on 'Genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=see_link&amp;anchor=H5#H5\">",
"     \"Introducing formula and solid foods to infants at risk for allergic disease\", section on 'Formula selection for the high risk infant'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=see_link&amp;anchor=H12#H12\">",
"     \"Introducing formula and solid foods to infants at risk for allergic disease\", section on 'Introduction of solid foods to high risk infants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17304?source=see_link\">",
"     \"The impact of breastfeeding on the development of allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20119?source=see_link\">",
"     \"Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FUTURE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no treatments that can cure or provide long-term remission from food allergy. However, several treatment strategies are under investigation. These approaches are either allergen-specific or aimed at modulating the overall allergic response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=see_link\">",
"     \"Future therapies for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with cow's milk allergy do not tolerate milk from sheep, goats, deer, ibex, and buffalo. However, some patients may tolerate milk from other mammals, such as camels, pigs, reindeer, horses, and donkeys. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cross-reactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of milk allergy includes instructions about avoidance of milk protein (",
"      <a class=\"graphic graphic_table graphicRef63271 \" href=\"mobipreview.htm?37/5/37980\">",
"       table 1",
"      </a>",
"      ), replacement of milk with alternative protein and calcium sources (",
"      <a class=\"graphic graphic_table graphicRef79377 \" href=\"mobipreview.htm?9/53/10075\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55081 \" href=\"mobipreview.htm?29/52/30539\">",
"       table 2",
"      </a>",
"      ), education in the proper management of accidental exposures (",
"      <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"       form 1",
"      </a>",
"      ), and monitoring for resolution of the allergy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjectors be prescribed for all patients with a history of anaphylactic reactions to milk (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that epinephrine autoinjectors be prescribed for all patients with milder IgE-mediated reactions to milk (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Acute IgE-mediated reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/1\">",
"      Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007; 120:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/2\">",
"      H&oslash;st A. Cow's milk protein allergy and intolerance in infancy. Some clinical, epidemiological and immunological aspects. Pediatr Allergy Immunol 1994; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/3\">",
"      Heine RG, Elsayed S, Hosking CS, Hill DJ. Cow's milk allergy in infancy. Curr Opin Allergy Clin Immunol 2002; 2:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/4\">",
"      J&auml;rvinen KM, Chatchatee P. Mammalian milk allergy: clinical suspicion, cross-reactivities and diagnosis. Curr Opin Allergy Clin Immunol 2009; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/5\">",
"      Bahna SL. Cow's milk allergy versus cow milk intolerance. Ann Allergy Asthma Immunol 2002; 89:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/6\">",
"      D'Auria E, Agostoni C, Giovannini M, et al. Proteomic evaluation of milk from different mammalian species as a substitute for breast milk. Acta Paediatr 2005; 94:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/7\">",
"      Restani P, Beretta B, Fiocchi A, et al. Cross-reactivity between mammalian proteins. Ann Allergy Asthma Immunol 2002; 89:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/8\">",
"      Bellioni-Businco B, Paganelli R, Lucenti P, et al. Allergenicity of goat's milk in children with cow's milk allergy. J Allergy Clin Immunol 1999; 103:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/9\">",
"      Vita D, Passalacqua G, Di Pasquale G, et al. Ass's milk in children with atopic dermatitis and cow's milk allergy: crossover comparison with goat's milk. Pediatr Allergy Immunol 2007; 18:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/10\">",
"      Ah-Leung S, Bernard H, Bidat E, et al. Allergy to goat and sheep milk without allergy to cow's milk. Allergy 2006; 61:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/11\">",
"      Tavares B, Pereira C, Rodrigues F, et al. Goat's milk allergy. Allergol Immunopathol (Madr) 2007; 35:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/12\">",
"      Katz Y, Goldberg MR, Zadik-Mnuhin G, et al. Cross-sensitization between milk proteins: reactivity to a \"kosher\" epitope? Isr Med Assoc J 2008; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/13\">",
"      Suutari TJ, Valkonen KH, Karttunen TJ, et al. IgE cross reactivity between reindeer and bovine milk beta-lactoglobulins in cow's milk allergic patients. J Investig Allergol Clin Immunol 2006; 16:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/14\">",
"      Businco L, Giampietro PG, Lucenti P, et al. Allergenicity of mare's milk in children with cow's milk allergy. J Allergy Clin Immunol 2000; 105:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/15\">",
"      Monti G, Bertino E, Muratore MC, et al. Efficacy of donkey's milk in treating highly problematic cow's milk allergic children: an in vivo and in vitro study. Pediatr Allergy Immunol 2007; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/16\">",
"      Alessandri C, Mari A. Efficacy of donkey's milk in treating cow's milk allergic children: major concerns. Pediatr Allergy Immunol 2007; 18:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/17\">",
"      Tesse R, Paglialunga C, Braccio S, Armenio L. Adequacy and tolerance to ass's milk in an Italian cohort of children with cow's milk allergy. Ital J Pediatr 2009; 35:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/18\">",
"      Bernard H, Negroni L, Chatel JM, et al. Molecular basis of IgE cross-reactivity between human beta-casein and bovine beta-casein, a major allergen of milk. Mol Immunol 2000; 37:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/19\">",
"      Han N, J&auml;rvinen KM, Cocco RR, et al. Identification of amino acids critical for IgE-binding to sequential epitopes of bovine kappa-casein and the similarity of these epitopes to the corresponding human kappa-casein sequence. Allergy 2008; 63:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/20\">",
"      M&auml;kinen-Kiljunen S, Plosila M. A father's IgE-mediated contact urticaria from mother's milk. J Allergy Clin Immunol 2004; 113:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/21\">",
"      Schulmeister U, Swoboda I, Quirce S, et al. Sensitization to human milk. Clin Exp Allergy 2008; 38:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/22\">",
"      J&auml;rvinen KM, Geller L, Bencharitiwong R, Sampson HA. Presence of functional, autoreactive human milk-specific IgE in infants with cow's milk allergy. Clin Exp Allergy 2012; 42:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/23\">",
"      Klemola T, Vanto T, Juntunen-Backman K, et al. Allergy to soy formula and to extensively hydrolyzed whey formula in infants with cow's milk allergy: a prospective, randomized study with a follow-up to the age of 2 years. J Pediatr 2002; 140:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/24\">",
"      Martelli A, De Chiara A, Corvo M, et al. Beef allergy in children with cow's milk allergy; cow's milk allergy in children with beef allergy. Ann Allergy Asthma Immunol 2002; 89:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/25\">",
"      Fiocchi A, Restani P, Riva E, et al. Heat treatment modifies the allergenicity of beef and bovine serum albumin. Allergy 1998; 53:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/26\">",
"      Vicente-Serrano J, Caballero ML, Rodr&iacute;guez-P&eacute;rez R, et al. Sensitization to serum albumins in children allergic to cow's milk and epithelia. Pediatr Allergy Immunol 2007; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/27\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/28\">",
"      Fiocchi A, Sch&uuml;nemann HJ, Brozek J, et al. Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol 2010; 126:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/29\">",
"      Fleischer DM, Perry TT, Atkins D, et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics 2012; 130:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/30\">",
"      Crotty MP, Taylor SL. Risks associated with foods having advisory milk labeling. J Allergy Clin Immunol 2010; 125:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/31\">",
"      Kim JS, Nowak-W��grzyn A, Sicherer SH, et al. Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol 2011; 128:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/32\">",
"      Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 2008; 121:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/33\">",
"      Lam HY, van Hoffen E, Michelsen A, et al. Cow's milk allergy in adults is rare but severe: both casein and whey proteins are involved. Clin Exp Allergy 2008; 38:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/34\">",
"      Macdougall CF, Cant AJ, Colver AF. How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across the UK and Ireland. Arch Dis Child 2002; 86:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/35\">",
"      Nowak-Wegrzyn A, Bloom KA, Sicherer SH, et al. Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 2008; 122:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/36\">",
"      Perry TT, Matsui EC, Conover-Walker MK, Wood RA. Risk of oral food challenges. J Allergy Clin Immunol 2004; 114:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/37\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/38\">",
"      David TJ. Anaphylactic shock during elimination diets for severe atopic eczema. Arch Dis Child 1984; 59:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/39\">",
"      Ito K, Morishita M, Ito A, et al. [Immediate type food hypersensitivity associated with atopic dermatitis in children]. Arerugi 2004; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/40\">",
"      Eller E, Kjaer HF, H&oslash;st A, et al. Food allergy and food sensitization in early childhood: results from the DARC cohort. Allergy 2009; 64:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40087/abstract/41\">",
"      Sicherer SH, Morrow EH, Sampson HA. Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol 2000; 105:582.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2391 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40087=[""].join("\n");
var outline_f39_9_40087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Allergy to other mammalian milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cross-reactivity to other protein sources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Alternatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical scenarios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acute IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Delayed gastrointestinal reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Monitoring for resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management of younger siblings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FUTURE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2391|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2391|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/5/37980\" title=\"table 1\">",
"      Ingredient label terms for milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/52/30539\" title=\"table 2\">",
"      Dietary alternatives to milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/53/10075\" title=\"table 3\">",
"      Infant hypoallergenic formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/16/17676\" title=\"table 4\">",
"      Nutritional comparison of milk to alternative sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/36/587\" title=\"table 5\">",
"      Toddler hypoallergenic formulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 6\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/20/36172\" title=\"table 7\">",
"      Symptoms and signs of anaphylaxis in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42759?source=related_link\">",
"      Food allergy: Impact on health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=related_link\">",
"      Future therapies for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=related_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29640?source=related_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7993?source=related_link\">",
"      Nutritional issues in food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20119?source=related_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17304?source=related_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40088="Sexual maturity rating of breast development in girls";
var content_f39_9_40088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72038%7EPEDS%2F79782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72038%7EPEDS%2F79782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sexual maturity rating (Tanner staging) of breast development in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 570px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stages in breast development in girls.",
"    <br>",
"     Stage 1: Prepubertal, with no palpable breast tissue.",
"     <br>",
"      Stage 2: Development of a breast bud, with elevation of the papilla and enlargement of the areolar diameter.",
"      <br>",
"       Stage 3: Enlargement of the breast, without separation of areolar contour from the breast.",
"       <br>",
"        Stage 4: The areola and papilla project above the breast, forming a secondary mound.",
"        <br>",
"         Stage 5: Recession of the areola to match the contour of the breast; the papilla projects beyond the countour of the areola and breast.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Figure from: Roede MJ, van Wieringen JC. Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheids 1985; 63:1. Reproduced with permission from the author.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sexual maturity rating (Tanner staging) of pubic hair development in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 564px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stages of development in pubic hair in girls.",
"    <br>",
"     Stage 1: Prepubertal with no pubic hair.",
"     <br>",
"      Stage 2: Sparse, straight hair along the lateral vulva.",
"      <br>",
"       Stage 3: Hair is darker, coarser, and curlier, extending over the mid-pubis.",
"       <br>",
"        Stage 4: Hair is adult-like in appearance, but does not extend to the thighs.",
"        <br>",
"         Stage 5: Hair is adult in appearance, extending from thigh to thigh.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Figure from: Roede MJ, van Wieringen JC. Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheids 1985; 63:1. Reproduced with permission from the author.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40088=[""].join("\n");
var outline_f39_9_40088=null;
var title_f39_9_40089="Periprocedural bleeding in patients undergoing percutaneous coronary intervention";
var content_f39_9_40089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     Paul Sorajja, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     David R Holmes, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40089/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/9/40089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advent of aggressive, multidrug antithrombotic therapy during percutaneous coronary intervention (PCI) has led to significant reductions in short- and long-term ischemic outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periprocedural bleeding is a frequent complication of PCI, and its frequency and severity is related in part to the intensity of antithrombotic therapy. Initially periprocedural bleeding was viewed as a relatively benign consequence, but recent data have linked the occurrence of bleeding and its treatment (ie, blood transfusion) to increased mortality and other adverse clinical outcomes.",
"   </p>",
"   <p>",
"    This topic reviews most aspects of periprocedural bleeding among patients undergoing PCI. Gastrointestinal bleeding in this setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding in relation to coronary artery bypass grafting or in association with diagnostic coronary angiography is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H8#H8\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Local vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of periprocedural bleeding during PCI lack precision due to the use of different definitions. In addition, relevant data come from differing patient populations who were treated with varying regimens of adjunctive pharmacology. Early studies of adjunctive pharmacology in PCI utilized definitions that were extrapolated from fibrinolytic trials (such as the TIMI and GUSTO scales). These early definitions focused on occurrence of intracranial bleeds or large drops in hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/1\">",
"     1",
"    </a>",
"    ]. In more recent studies, the definitions of major bleeding have been more inclusive of less severe, but clinically significant, bleeds (",
"    <a class=\"graphic graphic_table graphicRef71353 \" href=\"mobipreview.htm?28/0/28684\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    More recent trials have included the following events in the definition of major bleeding: the occurrence of intracranial or intraocular bleeding; significant decreases in hemoglobin (&ge;4",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    with overt bleeding or &ge;3",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    if no overt bleeding) or hematocrit (&gt;15 percent); need for transfusion; access site complications requiring surgery; or very large hematomas (&gt;5 cm).",
"   </p>",
"   <p>",
"    The heterogeneity in the definition of major bleeding at the time of PCI creates difficulty in conducting and interpreting the results of clinical research. For example, the relative safety (with regard to bleeding) of different antithrombotic agents may be difficult to ascertain when the combined safety end points across trials have different components. In 2011 the Bleeding Academic Research Consortium (BARC) published a consensus classification for bleeding (",
"    <a class=\"graphic graphic_table graphicRef77838 \" href=\"mobipreview.htm?11/37/11869\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/2\">",
"     2",
"    </a>",
"    ]. Validation of this definition needs to be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients enrolled in randomized trials and registries of adjunctive pharmacology for PCI, the incidence of major periprocedural bleeding ranged from 3 to 6 percent in reports published through 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In a 2012 report from the (US) National Cardiovascular Data Registry, the incidence was 1.7 percent (of over 3,000,000 procedures performed between 2004 and 2011) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Femoral access complications (eg, hematoma, pseudoaneurysm) are the most common type of periprocedural bleeding, accounting for approximately 60 percent of such events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Other frequent sites of bleeding are gastrointestinal (10 to 15 percent) and retroperitoneal (5 to 12 percent). Intracranial bleeding is less common (2 to 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined predictors of bleeding during and after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3-5,7,8\">",
"     3-5,7,8",
"    </a>",
"    ]. Consistent baseline predictors are age greater than 75 years, female gender, baseline anemia, and chronic kidney disease. The reasons for the predilection among women are not clear, but this relation becomes less evident after correction for gender-specific baseline differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In comparative PCI studies, women have been older, of smaller body weight, and with a greater prevalence of hypertension, diabetes, renal insufficiency, and acute coronary syndromes than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of the TRITON-TIMI 38 trial (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    ), which randomly assigned over 13,000 acute coronary syndrome patients undergoing planned PCI to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , evaluated potential risk factors for serious bleeding (defined as both TIMI major and TIMI minor bleeding) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition to those mentioned above, the following were identified: glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor use; duration of the intervention; ST-elevations myocardial infarction; hypercholesterolemia; and arterial hypertension.",
"   </p>",
"   <p>",
"    The most common periprocedural factors are sheath size (which at times is determined by the type of procedure), procedural duration, intra-aortic balloon pump placement, complexity of the intervention, and intensity and complexity of the antithrombotic regimen. Other risk factors include left main or three vessel disease, smoking, and INR &gt;2.6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Oral anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients scheduled for PCI are on long-term anticoagulant therapy, which increases the risk of periprocedural bleeding. The approach to such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor is an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    class I indication for PCI in the setting of unstable angina or non-ST-segment elevation myocardial infarction without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Thus, these drugs should not be withheld from such patients unless there are clear clinical contraindications. For low- to intermediate-risk patients adequately loaded with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and clopidogrel, addition of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor may not be of additional benefit and potentially could increase the risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/13\">",
"     13",
"    </a>",
"    ]. Use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors has been associated with a 1.4 to 2.7-fold increase in risk of periprocedural bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) is a mainstay of antithrombotic therapy for PCI. UFH reduces ischemic complications during PCI but excessive dosing leads to periprocedural bleeding. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Activated clotting time'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been compared to unfractionated heparin in several clinical trials. In the SYNERGY trial, patients with non-ST ACS and planned early invasive strategy were randomized to receive either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously every 12 hours, adjusted for creatinine clearance) or unfractionated heparin (60",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    bolus, then 12",
"    <span class=\"nowrap\">",
"     units/kg/hr",
"    </span>",
"    infusion). There was no difference in ischemic events, but the rate of TIMI major bleeding was higher in the enoxaparin group (9.1 percent versus 7.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H13#H13\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Heparins'",
"    </a>",
"    .) In comparison, two studies which compared enoxaparin using a dose of 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    compared to UFH before PCI found no difference in bleeding rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H22#H22\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Low molecular weight heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     Fondaparinux",
"    </a>",
"    is a selective antithrombin that has been compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    for treatment of non-ST-segment elevation acute coronary syndromes in the OASIS-5 study, in which 40 percent of patients had PCI. Patients randomized to fondaparinux had lower incidences of major bleeding (3.1 percent versus 5.0 percent) and death at 30 days (2.9 percent versus 3.5 percent). However, catheter-related thrombus was statistically more frequent in the fondaparinux group (0.9 percent versus 0.4 percent). There also has been concern that the dose of enoxaparin (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily, adjusted for creatinine clearance) may have been excessive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H39#H39\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Fondaparinux'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    monotherapy, in place of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, has been associated with a lower risk of periprocedural bleeding in several studies (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H18#H18\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Anticoagulation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the REPLACE-2 trial of 6010 patients undergoing urgent or elective PCI,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      with provisional",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      blockade reduced in-hospital major bleeding (2.4 percent versus 4.1 percent) in comparison to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      with planned",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      blockade without an increase in ischemic complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ISAR-REACT 3 randomized 4570 patients with stable or unstable angina who had been pretreated with 600 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      &ge;2 hrs before PCI in double-blind fashion to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      monotherapy. Bivalirudin led to a decrease in major bleeding at 30 days (3.1 percent versus 4.6 percent) but no net clinical benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/19\">",
"       19",
"      </a>",
"      ]. Paradoxically, subsequent analysis showed that the decrease in bleeding occurred mainly in patients who were at low risk of bleeding (eg, age &le;75 years, men, body weight &le;70 kg, no renal insufficiency, single vessel PCI), and that the reduction in bleeding risk was related to an increase in risk of myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial randomized 13,819 patients with unstable angina or non-ST-segment elevation myocardial infarction in open-label fashion to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      monotherapy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      with",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor inhibitor, or bivalirudin with",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor inhibitor. Bivalirudin monotherapy led to a statistically significant lower risk of major bleeding (3.0 percent versus 5.7 percent). There was a higher rate of ischemic events in patients not previously on a thienopyridine (9.1 percent versus 7.1 percent), although this interaction was of borderline statistical significance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the HORIZONS-AMI study, 3602 patients with ST-segment elevation myocardial infarction were randomized open-label to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      with",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor inhibitor. Bivalirudin use led to a statistically significantly, lower incidence of major bleeding (4.9 percent versus 8.3 percent), transfusion (2.1 percent versus 3.5 percent), thrombocytopenia (&lt;100,000",
"      <span class=\"nowrap\">",
"       platelets/mm3,",
"      </span>",
"      1.1 percent versus 2.9 percent), and 30-day death (2.1 percent versus 3.1 percent). Bivalirudin use also was associated with a higher incidence of stent thrombosis with 24 hours of PCI (1.3 percent versus 0.3 percent), although the 30-day rates were not different between the two study groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     P2Y12 platelet receptor inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , and cangrelor) have been studied in patients with acute coronary syndromes, the majority of whom underwent PCI (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H2#H2\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'antiplatelet therapy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TRITON-TIMI 38 trial of 13,608 with acute coronary syndromes and planned PCI,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      , in comparison to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , was associated with significantly lower rates of myocardial infarction (7.4 percent versus 9.7 percent) and stent thrombosis (1.1 percent versus 2.4 percent), but a higher rate of major bleeding (2.4 percent versus 1.8 percent), including life-threatening bleeding (1.4 percent versus 0.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the PLATO trial 18,624 patients with acute coronary syndrome, with or without ST-segment elevation, were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or clopidogrel; approximately 65 percent underwent PCI. Ticagrelor was associated with a significantly lower rates of death (4.5 percent versus 5.9 percent) and myocardial infarction (5.8 percent versus 6.9 percent), but led to a significantly higher rate of major bleeding (4.5 percent versus 3.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cangrelor, an intravenous, reversible adenosine diphosphate receptor antagonist, has been compared to 600 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      loading in two randomized trials. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H9#H9\">",
"       \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cangrelor'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the CHAMPION PCI trial, cangrelor resulted in no difference in individual or composite endpoints, although there was a trend for higher major bleeding using ACUITY criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/24\">",
"       24",
"      </a>",
"      ]. In CHAMPION PLATFORM, cangrelor did not lead to a reduction in the primary endpoint, but was associated with significantly lower rates of death (0.2 percent versus 0.7 percent) and stent thrombosis (0.2 percent versus 0.6 percent). Cangrelor also led to a significantly higher incidence of major bleeding using ACUITY criteria (5.5 percent versus 3.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprocedural bleeding has been linked to increased risk of early (in-hospital and 30-day). Studies of this relationship have come to differing conclusions when evaluating late (one-year) mortality (",
"    <a class=\"graphic graphic_figure graphicRef71180 \" href=\"mobipreview.htm?38/11/39102\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients enrolled in both randomized trials and various clinical registries, there is an approximate 3- to 10-fold increase in in-hospital and 30-day mortality for bleeding versus no bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/4-6,11,26-28\">",
"       4-6,11,26-28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      For example, in a 2012 report from the (US) National Cardiovascular Data Registry of over 3,000,000 procedures performed between 2004 and 2011, major bleeding was associated with increased in-hospital mortality (5.26 versus 1.87 percent; p &lt;.001) in a matched cohort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/6\">",
"       6",
"      </a>",
"      ]. In the entire cohort of individuals, the adjusted population attributable risk for mortality related to major bleeding was 12.1 percent.",
"      <br/>",
"      <br/>",
"      The increased risk of these events has been observed for both major and minor bleeding events, with a direct relation between severity and likelihood of poor outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/5,29\">",
"       5,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Periprocedural bleeding also is associated with prolonged hospital stay, intraprocedural complications (coronary perforation, embolization, dissection, ventricular fibrillation), and increased risk of myocardial infarction, stroke, renal failure, rehospitalization, and increased hospital costs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/4,6,28,30\">",
"       4,6,28,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether the mortality risk attributable to bleeding persists in late follow-up is unclear, with some studies suggesting a 2- to 4.5-fold increased risk of death at one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3,4,26,29\">",
"       3,4,26,29",
"      </a>",
"      ], with others finding no significant increase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Potential explanations for worse outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;While studies have clearly linked bleeding to adverse outcomes, it is difficult to determine whether bleeding is causative or simply a marker of heightened patient risk (",
"    <a class=\"graphic graphic_figure graphicRef76794 \" href=\"mobipreview.htm?18/24/18820\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/31\">",
"     31",
"    </a>",
"    ]. The local effect (eg, intracranial hemorrhage with mass effect) or torrential nature (eg, blood loss leading to severe hypotension) of a bleed may have profound clinical consequences. Nevertheless, comorbidity frequently is present in patients who bleed, and these morbidities often independently correlate with risk of death and nonfatal adverse events. Although the relation of bleeding to adverse outcomes remains significant after adjustment for these morbidities, statistical modeling cannot entirely account for baseline differences between patients with and without bleeding. This is particularly true when there are multiple covariates that are interrelated and also independently predict the outcomes of interest.",
"   </p>",
"   <p>",
"    Moreover, steps in clinical management taken to address bleeding do carry the potential to aggravate the risk of ischemic complications and subsequent mortality. Antithrombotic or antiplatelet therapy may be withheld in patients with bleeding, augmenting the risk of thrombotic complications such as coronary artery stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the GRACE registry, patients with acute myocardial infarction who bled had a higher frequency of discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , thienopyridines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Patients with bleeding who had discontinuation of these medications had a higher likelihood of in-hospital death in contrast to patients in whom these medications were continued despite bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/31\">",
"     31",
"    </a>",
"    ]. Notably, in the CADILLAC trial, the presence of anemia (with or without bleeding) was also associated with lower use of therapies known to improve survival in patients with acute coronary syndromes, such as beta-blockers, aspirin, and statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the challenges in discerning the causative role of bleeding, there are theoretical explanations for the increased risk of adverse events that have been observed. Bleeding leads to platelet activation and initiation of the clotting cascade to cause rapid local hemostasis. Mechanisms for preventing the systemic amplification of this response may be deficient in patients with vascular disease because such pathways are predominantly active within endothelial cells, potentially leading to a hypercoagulable state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/33\">",
"     33",
"    </a>",
"    ]. Erythropoietin, released in response to anemia, also may promote a prothrombotic state through activation of platelets and inducing plasminogen activator inhibitor-1, a procoagulant cytokine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This prothrombotic state may extend beyond the acute phase of erythropoietin release.",
"   </p>",
"   <p>",
"    Multiple studies have demonstrated periprocedural bleeding to be independently predictive of adverse events. In one study, using data from four randomized trials (ISAR-REACT, -REACT 2, -SWEET, and -SMART 2), the discriminatory power of bleeding for predicting one-year mortality was comparable to nonfatal myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/29\">",
"     29",
"    </a>",
"    ]. In a report from the ACUITY trial, in which 56 percent of patients with acute coronary syndromes underwent PCI, bleeding also was stronger than nonfatal myocardial infarction as a predictor of 30-day death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, there is evidence that less bleeding may be associated with fewer adverse events. Data from OASIS 5, HORIZONS-AMI, and radial access studies support the possibility that strategies associated with a lower risk of bleeding also lead to lower rates of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. The incidence and sequelae of periprocedural bleeding may be potentially ameliorable, but further study is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the factors predictive of bleeding during PCI are evident preprocedurally, allowing for the identification of patients at increased risk. A prognostic risk score for major bleeding during PCI has been developed with data from the REPLACE-1 and REPLACE-2 trials (",
"    <a class=\"graphic graphic_table graphicRef50176 \" href=\"mobipreview.htm?2/55/2940\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/7\">",
"     7",
"    </a>",
"    ]. Using a sum of weighted integers, examination of seven variables (age &gt;55 years, female gender, glomerular filtration rate &lt;60",
"    <span class=\"nowrap\">",
"     ml/1.73",
"    </span>",
"    m2, preexisting anemia, low-molecular-weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with 48 hours of PCI, glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor use, and intraaortic balloon pump use) allows one to estimate the risk of bleeding with a range of 1.0 percent for no risk factors up to 5.4 percent for high-risk patients. While this prognostic score examined only patients with femoral access and has yet to be validated in less selected, \"real world\" registries, this assessment nevertheless does allow identification of high-risk patients who may benefit from relatively closer observation after PCI. As there are no established approaches to the management of patients at high risk, an individualized approach should be used for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Femoral access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the vast majority of periprocedural bleeds occur at the vascular access site, meticulous attention to the methods for vascular access (eg, avoidance of posterior wall puncture and puncture too high or too low), proper hemostasis, and appropriate sheath management (ie, use of smaller size, shorter duration of insertion) reduces the incidence of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Hemostasis at the access site'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59457818\">",
"    <span class=\"h2\">",
"     Radial access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of radial, as opposed to common femoral, artery access in preventing periprocedural bleeding is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H23#H23\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Activated clotting time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of activated clotting time (ACT) is important for minimizing the risk of such bleeding. For PCI without GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, goal activated clotting times generally are 300 to 350 seconds. For patients receiving an",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor inhibitor, goal activated clotting times are lower (200 to 250s) because these drugs suppress thrombin activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/37\">",
"     37",
"    </a>",
"    ]. Of note, post-procedural UFH in PCI patients is associated with a &ge;2.5 fold increase the risk of periprocedural bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients on oral anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients on oral anticoagulants at the time of PCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H32#H32\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Patients who require warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vascular closure devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of note, the use of vascular closure devices has not been shown to reduce the incidence of periprocedural bleeding, but may in fact increase its occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/5,38,40\">",
"     5,38,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprocedural bleeding may occur from vascular access site trauma or remotely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Local vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound normally suffices for evaluation of local trauma and can be used to guide therapy (eg, thrombin injection for pseudoaneurysm). Occult bleeding should be suspected in patients with unexplained altered neurologic findings, hypotension, clinical or hemodynamic instability, or significant drops in hemoglobin or hematocrit. Retroperitoneal bleeding usually is associated with femoral access above the inguinal ligament, posterior wall femoral puncture, or inadvertent perforation of the aortoiliac vessels with guidewire or catheter advancement. Retroperitoneal bleeding may present as hypotension and bradycardia during sheath removal, and thus may be mistaken for hypervagotonia. For suspected bleeding remote from the vascular access site, computed tomographic imaging of the body or head (without contrast) is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt recognition, timely evaluation, achievement of hemostasis, and, when appropriate, reversal of anticoagulation, are fundamental in the management of periprocedural bleeding. Management of specific complications of periprocedural bleeding related to PCI is discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Reversal of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversal of the effect of anticoagulation should be considered in patients with life-threatening bleeding, need for open surgery to correct the etiology of bleeding, or for those in whom hemostasis cannot be achieved. Because reversal of anticoagulation theoretically may promote thrombogenicity, reversal should be sought only with careful consideration of the potential benefits and risks to the patient. Patients with recent intracoronary stent implantation should continue to receive dual antiplatelet therapy to ameliorate the risk of acute stent thrombosis according to the recommendations of the",
"    <span class=\"nowrap\">",
"     AHA/ACC/SCAI/ACS/ADA",
"    </span>",
"    Science Advisory guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous protamine rapidly reverses the effects of UFH and, to a lesser extent, that of low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Protamine has been shown to facilitate early sheath removal after PCI, although one report has reported potential harm after placement of drug-eluting stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/37,39,42\">",
"     37,39,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin reversal with protamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , there is no agent for reversal of its effects, but the therapeutic half-life of the drug is relatively short (25 min in patients with normal renal function). A discussion of the emergency treatment of bleeding in patients on anticoagulants other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H32#H32\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Emergency treatment of bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with bleeding on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , either fresh frozen plasma (2 to 3 units)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin K should be administered. Vitamin K, when given intravenously (0.5 to 3 mg), should be infused slowly with doses adjustment according to urgency of the bleeding, and with awareness of the potential for anaphylaxis when administered via this route. Of note, there is no difference in effectiveness of vitamin K given orally or intravenously 24 hours after administration. Thus, oral vitamin K (1 to 3 mg) can be used in patients who do not need immediate reversal of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Reversal of GPIIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors increase the risk of periprocedural bleeding. Platelet transfusion is effective for reversing the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , but is less effective against the small molecule GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    ). For the small molecule agents, the biologic half-life with dosing adjusted for creatinine clearance is approximately 2.5 hours. The management of thrombocytopenia induced by GP",
"    <span class=\"nowrap\">",
"     IIb/IIIA",
"    </span>",
"    inhibitors is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24918?source=see_link&amp;anchor=H12#H12\">",
"     \"Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood transfusion is often considered, particularly as a large number of studies have linked anemia and bleeding to adverse outcomes. However, while these observations have suggested that optimization of hemoglobin may be preferred, blood transfusion for periprocedural bleeding in fact has been linked to increased mortality after PCI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the British Columbia registry of PCI patients, transfused patients, in comparison to nontransfused, had significantly increased 30-day (12.6 percent versus 1.3 percent) and one-year mortality (22.3 percent versus 3.2 percent). Notably, the rates of transfusion and mortality were 40 to 50 percent lower when radial access was used in place of femoral access [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two separate registry studies (one of 17,901 patients from Mayo Clinic and one of 10,974 patients from Washington Hospital) have demonstrated incremental risk of death with increasing transfusion requirements after PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. In the Mayo Clinic study, increased mortality was demonstrated in patients who received only one or two units of blood in comparison to nontransfused patients, with follow-up extending to six years after PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Potential mechanisms of adverse outcome after blood cell transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in need of blood cell transfusion after PCI have been found to be older and have greater comorbidity than nontransfused patients. Adjustment for these baseline characteristics using either multivariate models",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    propensity analyses has shown transfusion to be an independent predictor of both in-hospital and one-year survival. While statistical methods cannot fully account for retrospective bias, several explanations, in addition to bias, have been proposed to help explain the link between blood transfusion and excess mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rises in hemoglobin level with blood cell transfusion increase oxygen delivery, but measures of tissue oxygenation do not change or, in fact, may decrease. Storage of red blood cells may lead to less deformability and more fragility of the cell, reduced nitric oxide activity (resulting in less vasodilatation during decoupling of oxygen delivery), and depletion of 2,3-diphosphoglyceric acid (leading to reduced tissue extraction of oxygen) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/44-48\">",
"       44-48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transfusion may be prothrombotic, due to enhancement of procoagulant protein plasminogen activator inhibitor (PAI)-1 content during cell storage, acute platelet release of CD40 ligand during transfusion, release of adenosine diphosphate from stored red blood cells that leads to platelet activation, and relative deficiencies in nitric oxide in the transfused blood products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemolytic reactions and the consequences of large-volume transfusion (eg, coagulopathy, electrolyte disturbances) may lead to increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physiologic changes in red blood cells that occur with storage are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of red blood cells for transfusion\", section on 'Physiologic changes with storage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Recommendations for blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;General recommendations for transfusion are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been no randomized studies of blood transfusion for patients undergoing PCI. Recommendations are extrapolated from studies in other patient populations and should be individualized. An arbitrary cut-off for hemoglobin (or hematocrit) to indicate need for transfusion is not recommended. In a Canadian study of 357 critically ill patients with cardiovascular disease, a restrictive transfusion policy (transfusion for hgb &lt;7.0",
"    <span class=\"nowrap\">",
"     g/dl),",
"    </span>",
"    in comparison to a liberal policy (transfusion for hgb &lt;10.0",
"    <span class=\"nowrap\">",
"     g/dl),",
"    </span>",
"    was associated with less multiorgan dysfunction but no difference in 30-day mortality (23 percent for both groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The authors did report a trend toward less 30-day survival in the restrictive policy group among the patients with acute myocardial infarction or unstable angina (21 percent versus 26 percent), but this difference was not significant. In a separate study of patients with acute coronary syndromes, the predicted probability of 30-day death was higher with transfusion at nadir hematocrit values above 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/53\">",
"     53",
"    </a>",
"    ]. Conversely, another study of elderly patients with acute myocardial infarction demonstrated mortality benefit for transfusion for hematocrit less than 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with periprocedural bleeding and who have severe symptoms of angina or dyspnea (class &ge;III or lifestyle impairment) or have evidence of myocardial ischemia despite revascularization, it is reasonable to transfuse. The clinical threshold for transfusion may be lower in those with acute coronary syndromes, as the risk of anemia appears to be greater in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40089/abstract/7,54\">",
"     7,54",
"    </a>",
"    ]. In the absence of such findings, the net benefit may be minimal with significant potential for harm. One exception may be an asymptomatic patient who is at high risk from rebleeding from a noncompressible site, in whom a greater reserve of red cell mass may be desired. Randomized trials to determine the role of transfusion for PCI patients with bleeding are needed.",
"   </p>",
"   <p>",
"    The general discussion of indication for red cell transfusion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprocedural bleeding is associated with adverse outcomes including a fourfold or greater increase in early and late mortality. The cause of adverse outcomes is often multifactorial and includes the local effects of the bleed, excess patient morbidity that is frequently present in those who bleed, and potential harm from therapy taken to address occurrence of bleeding. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Clinical outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Periprocedural bleeding occurs in three to six percent of cases. Risk factors include age greater than 75 years, female gender, baseline anemia, and chronic kidney disease, sheath size, procedural duration, intra-aortic balloon pump placement, complexity of the intervention, and intensity and complexity of the antithrombotic regimen. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Incidence'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prevention includes identification of patients at high risk, meticulous attention to the access site, including consideration of radial access, and proper use of the activated clotting time. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Management of periprocedural bleeding must be individualized as each intervention aimed at terminating the bleeding may adversely impact outcome. Interventions include reversal of anticoagulation and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, and blood transfusion. While blood transfusion is often considered for patients who bleed, it has been linked to increased mortality after PCI. Therefore, blood transfusion should only be undertaken after careful consideration of the potential benefit and risks to the patient. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Periprocedural and long-term gastrointestinal bleeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25592511\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/1\">",
"      Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/2\">",
"      Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/3\">",
"      Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/4\">",
"      Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/5\">",
"      Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008; 1:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/6\">",
"      Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013; 309:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/7\">",
"      Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/8\">",
"      Iijima R, Ndrepepa G, Mehilli J, et al. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J 2009; 30:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/9\">",
"      Fernandes LS, Tcheng JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. J Am Coll Cardiol 2002; 40:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/10\">",
"      Chacko M, Lincoff AM, Wolski KE, et al. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006; 151:1032.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/11\">",
"      Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011; 123:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/12\">",
"      Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/13\">",
"      Kastrati A, Mehilli J, Sch&uuml;hlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/14\">",
"      Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/15\">",
"      Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/16\">",
"      Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/17\">",
"      Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/18\">",
"      Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/19\">",
"      Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/20\">",
"      Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/21\">",
"      Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/22\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/23\">",
"      Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/24\">",
"      Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/25\">",
"      Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009; 361:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/26\">",
"      Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/27\">",
"      Jani SM, Smith DE, Share D, et al. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol 2007; 30:II49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/28\">",
"      Yatskar L, Selzer F, Feit F, et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 2007; 69:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/29\">",
"      Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/30\">",
"      Kim P, Dixon S, Eisenbrey AB, et al. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol 2007; 30:II35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/31\">",
"      Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007; 116:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/32\">",
"      Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004; 44:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/33\">",
"      Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/34\">",
"      Taylor JE, Henderson IS, Stewart WK, Belch JJ. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/35\">",
"      Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/36\">",
"      Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/37\">",
"      Ducas J, Chan MC, Miller A, Kashour T. Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients. Catheter Cardiovasc Interv 2002; 56:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/38\">",
"      Koreny M, Riedm&uuml;ller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/39\">",
"      Cosgrave J, Qasim A, Latib A, et al. Protamine usage following implantation of drug-eluting stents: a word of caution. Catheter Cardiovasc Interv 2008; 71:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/40\">",
"      Ellis SG, Bhatt D, Kapadia S, et al. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 67:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/41\">",
"      Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/42\">",
"      Briguori C, Di Mario C, De Gregorio J, et al. Administration of protamine after coronary stent deployment. Am Heart J 1999; 138:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/43\">",
"      Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008; 94:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/44\">",
"      Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/45\">",
"      Almac E, Ince C. The impact of storage on red cell function in blood transfusion. Best Pract Res Clin Anaesthesiol 2007; 21:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/46\">",
"      Anniss AM, Sparrow RL. Variable adhesion of different red blood cell products to activated vascular endothelium under flow conditions. Am J Hematol 2007; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/47\">",
"      Berezina TL, Zaets SB, Morgan C, et al. Influence of storage on red blood cell rheological properties. J Surg Res 2002; 102:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/48\">",
"      Allen BW, Piantadosi CA. How do red blood cells cause hypoxic vasodilation? The SNO-hemoglobin paradigm. Am J Physiol Heart Circ Physiol 2006; 291:H1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/49\">",
"      Twomley KM, Rao SV, Becker RC. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombolysis 2006; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/50\">",
"      Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002; 1:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/51\">",
"      H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/52\">",
"      H&eacute;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/53\">",
"      Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40089/abstract/54\">",
"      Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345:1230.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1573 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40089=[""].join("\n");
var outline_f39_9_40089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Oral anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - P2Y12 platelet receptor inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Potential explanations for worse outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Femoral access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59457818\">",
"      Radial access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Activated clotting time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients on oral anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vascular closure devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Reversal of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Reversal of GPIIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Potential mechanisms of adverse outcome after blood cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Recommendations for blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25592511\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1573|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/11/39102\" title=\"figure 1\">",
"      Mortality after periprocedural bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/24/18820\" title=\"figure 2\">",
"      Mechanisms linkng periprocedural bleeding and death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/0/28684\" title=\"table 1\">",
"      Definitions major bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/37/11869\" title=\"table 2\">",
"      BARC definition for bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/55/2940\" title=\"table 3\">",
"      Algorithm for predicting peri-procedural bleeding during PCI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24918?source=related_link\">",
"      Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40090="Management of type 1 diabetes mellitus in children and adolescents";
var content_f39_9_40090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of type 1 diabetes mellitus in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Madhusmita Misra, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/9/40090/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/9/40090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus, one of the most common chronic diseases in childhood, is caused by insulin deficiency resulting from the destruction of insulin-producing pancreatic beta cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are unique challenges in caring for children and adolescents with diabetes that differentiate pediatric from adult care. These include the obvious differences in the size of the patients, developmental issues such as the unpredictability of a toddler's dietary intake and activity level, and medical issues such as the increased risk of hypoglycemia and diabetic ketoacidosis. Because of these considerations, the management of a child with type 1 diabetes must take into account the age and developmental maturity of the child.",
"   </p>",
"   <p>",
"    Although most children with type 1 diabetes present with the classic signs and symptoms of hyperglycemia without accompanying acidosis, approximately 30 percent of children in the United States present with diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/1\">",
"     1",
"    </a>",
"    ]. The management of these patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of the child or adolescent with type 1 diabetes, who either did not present with ketoacidosis or who has recovered from ketoacidosis, will be reviewed here. The term parent will be used throughout the discussion, with recognition that the primary caregiver may not be a parent.",
"   </p>",
"   <p>",
"    The presentation, diagnosis, and complications of childhood-onset type 1 diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of children with diabetes includes the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balancing strict glycemic control, which reduces the risk of long-term sequelae, and avoidance of severe hypoglycemia, which is more likely with stricter control. In children, targeted glycemic goals define what is thought to be the best balance between these long- and short-term complications. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Glycemic control'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Setting realistic goals for each child and family. The patient's age and developmental status, and the level of family involvement are important factors in establishing a practical management plan that can be implemented by the patient and family. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Age-based care'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Maintaining normal growth, development, and emotional maturation. Increasing independence and self-care as the child grows is an ongoing goal.",
"     </li>",
"     <li>",
"      Training the patient and family to provide appropriate daily diabetes care in order to attain glucose control within the range of predetermined goals, and to recognize and treat hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21606?source=see_link\">",
"       \"Self-management education for the child with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial diabetes education and self-care training should be provided by a multidisciplinary team for the patient and family to acquire the knowledge and skills needed for care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. Team members should include an endocrinologist, nurse educator, dietitian, and a mental health professional, who can provide pediatric-specific education and care. Comprehensive management by a pediatric diabetes team reduces the number of hospitalizations and emergency room visits and is cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Training and care of the patient and family is divided into two management phases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial management &mdash; Initiate therapy with insulin and teach the patient and family the age-appropriate essential skills for optimal diabetes care",
"     </li>",
"     <li>",
"      Ongoing management &mdash; Continued care, education, and support for the child and family",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial phase begins at the time of diagnosis. In these first few days, the family begins to understand the disease process and is trained to successfully administer insulin, check blood glucose concentrations, check for ketonuria, and recognize and treat hypoglycemia (",
"    <a class=\"graphic graphic_table graphicRef71840 \" href=\"mobipreview.htm?18/29/18909\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic understanding &mdash; The diabetes team teaches the patient and family the cause and treatment of type 1 diabetes, how to maintain a daily schedule and record of blood glucose test results, insulin administration, and the timing and carbohydrate content of meals and snacks.",
"     </li>",
"     <li>",
"      Insulin administration &mdash; Training includes teaching the family about the different types of prescribed insulin, how to measure and inject insulin, and how to rotate injection sites. Family members and caretakers must learn about the duration and action of the various types of insulin prescribed for their child. They must also understand how to adjust the insulin dose based upon blood glucose concentrations and carbohydrate intake. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Insulin'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"       \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In our practice, we encourage the parents to administer the first injection. Although this requires additional assistance and fairly directive behavior on the part of the clinician, we find that it facilitates the learning process. Because most parents are so frightened about administering an injection to their child, their ability to learn is limited until they have administered the first injection. We also find it useful to have the parents administer a saline injection to themselves, so that they realize the discomfort is minimal.",
"     </li>",
"     <li>",
"      Blood glucose testing &mdash; Families must master blood glucose testing with one of many meters which are easy to use. They are instructed on the frequency and timing of monitoring depending upon the needs of their child. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"       \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Blood glucose monitoring'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ketonuria &mdash; Families are taught to check urine for ketones at times of illness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if two consecutive blood glucose readings are greater than 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"       \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H14#H14\">",
"       \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hyperglycemia and DKA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoglycemia &mdash; Families are taught to recognize the signs and symptoms of hypoglycemia. Detection of hypoglycemia is particularly difficult in the non-verbal young child and infant in whom the signs of hypoglycemia are nonspecific. Parents are trained to check a blood glucose level and, if this is too low, to intervene with dietary measures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"       \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Age-based care'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial educational and care phase may occur either in the inpatient or ambulatory setting. Most institutions have moved from prolonged inpatient admissions for newly diagnosed patients to either short hospitalizations or exclusively ambulatory management. Patient outcome is similar with outpatient and inpatient management, regardless of the length of inpatient hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We initiate the care of most newly diagnosed children with type 1 diabetes without ketoacidosis in the outpatient setting. A multidisciplinary team provides close follow-up (daily phone contact and ambulatory visits as necessary), comprehensive education, and an individualized management plan for the child and family.",
"   </p>",
"   <p>",
"    Once the family and care providers are comfortable with the family's ability to manage the child's diabetes at home, plans should be made to return the child to school or daycare center, as appropriate. If insulin needs to be administered at the child's school or daycare center, a responsible individual must be identified and trained in basic diabetes management skills. In addition, appropriate individuals at the school or daycare center must be provided with information regarding the detection and management of hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=see_link&amp;anchor=H5#H5\">",
"     \"Special situations in children and adolescents with type 1 diabetes mellitus\", section on 'School and daycare'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with diabetes should wear a medical emergency",
"    <span class=\"nowrap\">",
"     bracelet/necklace",
"    </span>",
"    to enable suitable intervention by emergency personnel should an emergency situation arise (ie, hypoglycemia or diabetic ketoacidosis). MedicAlert provides an excellent resource (",
"    <a class=\"external\" href=\"file://www.medicalert.org/\">",
"     www.medicalert.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ongoing management",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial phase, the diabetes team continues to provide care, teaching, and support to the child and family. Sessions with individual team members (endocrinologist, nurse educator, dietitian, and a mental health professional) allow more in-depth education and care directed toward the goal of maintaining excellent glucose control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21606?source=see_link\">",
"     \"Self-management education for the child with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During these sessions, the concepts that are required for glycemic control are stressed including the interaction of insulin, diet, and exercise on blood glucose concentrations. A management regimen specific for each patient is designed to achieve the best possible glucose control. In addition, the requirement for strict glycemic control to prevent long-term sequelae of diabetes is emphasized and repeated as often as necessary, particularly if glycemic control is suboptimal.",
"   </p>",
"   <p>",
"    Providing age-appropriate psychosocial support for the patient and the family by a proficient mental health professional improves adherence to the management plan. In two controlled trials, structured psychoeducational support significantly improved glycemic control and reduced hospitalization rates in adolescents whose diabetes had previously been poorly controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the child grows older, education and training are directed toward increased autonomy and self-management for the patient. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Age-based care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Printed literature and Web sites available for patient and family education are excellent supplements to the teaching provided by the diabetes team (",
"    <a class=\"graphic graphic_table graphicRef71046 \" href=\"mobipreview.htm?23/33/24091\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AGE-BASED CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management plan of childhood-onset type 1 diabetes is dependent upon the age of the patient, which impacts the risk of hypoglycemia and development of self-management skills:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age-specific goals for glycemic control are based upon the risk of hypoglycemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Age-specific goals'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"       \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ability of the child to participate in self-management varies with the age, cognitive ability, and emotional maturity of the child or adolescent (",
"      <a class=\"graphic graphic_table graphicRef53457 \" href=\"mobipreview.htm?14/6/14445\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion on age-based management is compatible with the American Diabetes Association (ADA) guidelines for the care of children and adolescents with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants (younger than 1 year of age) with diabetes have the highest risk of severe hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. Hypoglycemia is difficult to detect because infants are unable to communicate their symptoms and clinical signs are nonspecific (eg, poor feeding, lethargy, jitteriness, hypotonia).",
"   </p>",
"   <p>",
"    Hypoglycemia can also lead to neurologic complications. Infants with severe hypoglycemia can present with seizures or coma, which may have permanent neurologic sequelae. In addition, repeated episodes of hypoglycemia as well as persistent hyperglycemia may have deleterious effects on brain development and learning, especially in children younger than five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequent feeding schedule of infancy makes it challenging to develop a management plan that avoids episodes of hypoglycemia but provides sufficient glycemic control. In addition, the stress of implementing the daily care plan can have adverse effects on parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Toddlers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issues surrounding the care of toddlers (1 to 3 years of age) are similar to those in infants. The parents must learn and be responsible for the daily care of the patient and also learn to recognize episodes of hypoglycemia. Hypoglycemia is a constant concern because of the erratic food intake and activity levels of toddlers. It also can be difficult to distinguish developmentally normal episodes of oppositional behavior and temper tantrums from altered behavior caused by hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. The parents must learn to measure blood glucose before ignoring a temper tantrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preschool and early school-aged children",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the most part, parents still provide daily care for preschool and early school-aged children (3 to 7 years of age). However, some of these patients can begin to participate in their own care by testing their blood glucose or preparing materials. Often, such mastery behaviors are short-lived, as the children rapidly become bored and wish to forgo such responsibilities. The parents must be counseled that this behavior is normal and age appropriate. As these children enter daycare or school, childcare providers and school nurses must be involved in their diabetes care. For parents, sharing care with others including the patient may be difficult. Continued support by the care team is important to facilitate this transition. Shared care with the child is appropriate at this age only under direct parental supervision. In the United States, children younger than six years may be eligible to receive supplemental Social Security income to help their parents with the economic impact of diabetes management in the young child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=see_link&amp;anchor=H5#H5\">",
"     \"Special situations in children and adolescents with type 1 diabetes mellitus\", section on 'School and daycare'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     School-aged children",
"    </span>",
"    &nbsp;&mdash;&nbsp;School-aged children (8 to 11 years of age) can assume more of the daily management of their diabetes with adult supervision and support. They can learn to administer insulin injections on a routine basis, but still need significant assistance and supervision for management decisions that are not routine. All glucose testing and insulin administration should be under adult supervision. Early independent self-management in this age group with minimal or no adult supervision results in poorer glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Shared responsibility with appropriate adult supervision needs to be established for optimal care.",
"   </p>",
"   <p>",
"    The diagnosis of diabetes has a psychological impact on these children, which may be manifested by depression and anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Children may also have difficulty with social interactions because of their perception that they are different from their peers. The parents and the diabetes team need to ensure that children regularly attend school and encourage participation in school activities to develop normal peer relationships [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts recommend routine screening for behavioral disturbances in children with diabetes at diagnosis, and suggest that at-risk children may subsequently benefit from evaluation of parental mental health and family dynamics. It is important for caregivers to recognize developing cognitive deficits and learning difficulties, and for appropriate care to be provided to children if these deficits develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/20\">",
"     20",
"    </a>",
"    ]. This is particularly important because of the higher risk of cognitive deficits in children who developed diabetes at a very young age, those with poor glycemic control, frequent episodes of hypoglycemia and longer duration of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H12#H12\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Neurologic sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the appropriate extent of adult involvement during a normal developmental period of increasing independence and self-assertiveness is challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/21\">",
"     21",
"    </a>",
"    ]. Although adolescents can be responsible for the daily management of their diabetes, minimal or no adult supervision results in poor glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. However, parent-child conflict over daily management also leads to poor control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In contrast, shared management between the adolescent and parents has been associated with better glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family-focused teamwork, which includes developing shared parent-child responsibility and strategies to avoid conflict, improves the care of the older child with diabetes. This was illustrated in a controlled trial of family-focused teamwork compared to standard multidisciplinary diabetes care in children who ranged from 8 to 17 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/26\">",
"     26",
"    </a>",
"    ]. Family-focused care, which included establishing a responsibility-sharing plan at the end of each patient visit and active family discussion, increased family involvement and resulted in better glycemic control (adjusted glycated hemoglobin [A1C], 8.8 versus 9.3 percent). This approach allows the care team to develop a shared responsibility plan that is appropriate for the patient based upon",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    cognitive, physical, and psychosocial maturity.",
"   </p>",
"   <p>",
"    Other issues for the adolescent patient with diabetes include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Driving &mdash; Adolescent drivers with diabetes should be taught to test blood glucose levels before driving. Data in adults demonstrate that a significant number of patients considered it safe to drive when they were hypoglycemic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/28\">",
"       28",
"      </a>",
"      ]. It is essential for teenagers to understand the risks of driving while hypoglycemic and to be urged to carry carbohydrate snacks with them at all times. If hypoglycemic when they test their blood sugar before driving, they should take a carbohydrate snack and confirm normalization of blood sugar before driving.",
"     </li>",
"     <li>",
"      Risky behavior &mdash; Adolescence is also a time period that is characterized by experimentation with risky behaviors, such as alcohol and drug use and unprotected sexual intercourse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alcohol intake can be associated with severe hypoglycemia. Adolescents should be aware of this risk, routinely assessed for alcohol use, and counseled, if appropriate.",
"     </li>",
"     <li>",
"      Smoking is an important risk factor for long-term diabetic complications. Counseling about smoking avoidance (or cessation if appropriate) should be an important part of ongoing care. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=see_link\">",
"       \"Management of smoking cessation in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Before initiating sexual activity, adolescent girls should be given preconception counseling that includes the risks of diabetes complications to themselves and potentially the fetus. Use of contraception should be reviewed and encouraged. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=see_link\">",
"       \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link\">",
"       \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychiatric issues &mdash; Adolescent patients with diabetes have a threefold increased risk of psychiatric disorders, primarily depression and eating disorders. Eating disorders may take the form of intentional misuse of insulin for weight control, and symptoms of disordered eating and the possibility of intentional insulin misuse should be specifically investigated. Annual screening for depression should be initiated for children &ge;10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H17#H17\">",
"       \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Psychiatric disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the adolescent approaches young adulthood, there should be an orderly transition to independent self-management with support from the family and diabetes team [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15751005\">",
"    <span class=\"h2\">",
"     Transition into adult care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the issues discussed above should also be monitored during and after the transition to adult care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Risk for eating disorders, including intentional insulin misuse",
"     </li>",
"     <li>",
"      Contraception and education to minimize the maternal and fetal risks of pregnancy",
"     </li>",
"     <li>",
"      Education about the adverse effects of alcohol on glycemic control, and of tobacco on the cardiovascular complications of diabetes",
"     </li>",
"     <li>",
"      Prevention and management of hypoglycemic episodes while driving",
"     </li>",
"     <li>",
"      Possibility of discontinuation of insurance coverage, and education regarding insurance options and maintenance of coverage",
"     </li>",
"     <li>",
"      Education regarding expectation of greater autonomy in the adult diabetes clinic &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Young adults tend to decrease the frequency of contact with their diabetes care provider after transition to an adult program, and those with fragmented care have poorer glycemic control and a higher rate of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/29\">",
"     29",
"    </a>",
"    ]. Techniques to facilitate transition to adult health care include longer or more frequent initial visits, use of a transition coordinator, or transition to a clinic designed for young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/27\">",
"     27",
"    </a>",
"    ]. The National Diabetes Education Program has developed a",
"    <a class=\"external\" href=\"file://ndep.nih.gov/transitions/\">",
"     transition planning template",
"    </a>",
"    to facilitate transitions from pediatric to adult care; this includes a checklist for the pediatric provider, a list of key health information to be transferred, and patient information resources designed for this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily blood glucose levels are used to monitor glycemic control and adjust management. The most widely used clinical test to evaluate long-term glycemic control is blood glycated hemoglobin (also called A1C, hemoglobin A1C, glycohemoglobin, or glycosylated hemoglobin). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"     \"Estimation of blood glucose control in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both in children and adults, the goal of management is to maintain glucose control as near to normal as safely possible (ie, balance the risks of long-term complications of diabetes and hypoglycemia). The targeted goal of this glycemic balance varies based upon the risk of hypoglycemia, which is age dependent.",
"   </p>",
"   <p>",
"    In adults, an A1C value of 7 percent or less is the targeted goal that best balances the risks of long-term sequelae and hypoglycemia. This was illustrated by the Diabetes Control and Complications Trial (DCCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term complications &mdash; Strict glycemic control delayed the onset of microvascular disease (retinopathy, nephropathy, and neuropathy), slowed progression of already-present microvascular disease, and decreased the incidence of cardiovascular disease. As A1C decreased, so did the risk of long-term sequelae, such as diabetic retinopathy (",
"      <a class=\"graphic graphic_figure graphicRef82664 \" href=\"mobipreview.htm?42/55/43901\">",
"       figure 1",
"      </a>",
"      ). Randomized trials in adolescents have shown a similar relationship between glycemic control and long-term microvascular sequelae of diabetes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"       \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoglycemia &mdash; The DCCT demonstrated that as A1C decreased, the incidence of severe hypoglycemic episodes increased (",
"      <a class=\"graphic graphic_figure graphicRef59452 \" href=\"mobipreview.htm?5/41/5789\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is a continued relative risk reduction of retinopathy and other complications at A1C values below 7 percent, the absolute risk of developing these complications is low if the A1C value is kept below this threshold (",
"    <a class=\"graphic graphic_figure graphicRef82664 \" href=\"mobipreview.htm?42/55/43901\">",
"     figure 1",
"    </a>",
"    ). Conversely, the absolute risk of severe hypoglycemia increases progressively (",
"    <a class=\"graphic graphic_figure graphicRef59452 \" href=\"mobipreview.htm?5/41/5789\">",
"     figure 2",
"    </a>",
"    ). Therefore, an A1C goal of 7 percent has been recommended as a goal that balances the long- and short-term risks in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Age-specific goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents, there are no comparable data to determine the optimal target goal for A1C levels. The intensity of glycemic control needs to be balanced against the increased risk of recurrent hypoglycemia and the consequences of severe hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/3,4,32\">",
"     3,4,32",
"    </a>",
"    ]. This was illustrated in a retrospective review of 709 children with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/32\">",
"     32",
"    </a>",
"    ]. In this cohort, as the A1C fell from 10.2 to 8.8, there was an increase in the episodes of hypoglycemia (4.8 to 15.6 episodes per 100 patient years). The increase in episodes of hypoglycemia was greatest in children younger than 6 years of age (14.0 to 42.1 episodes per 100 patient years). A subsequent report of the same cohort revealed that further decreases in A1C were achieved without concomitant increases in the frequency of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Targeted goals for A1C and blood glucose have been defined by a committee of the American Diabetes Association (ADA) based upon the risk of hypoglycemia, with the highest target values set for young children and infants because they have the greatest risk for hypoglycemia (",
"    <a class=\"graphic graphic_table graphicRef63148 \" href=\"mobipreview.htm?27/26/28076\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Age-based care'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Age-specific goals for A1C are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;6 years of age: &lt;8.5 percent",
"     </li>",
"     <li>",
"      6 to 12 years of age: &lt;8 percent",
"     </li>",
"     <li>",
"      13 to 19 years of age: &lt;7.5 percent",
"     </li>",
"     <li>",
"      Over 19 years of age: &lt;7.0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age-specific goals for blood glucose at bedtime are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;6 years of age: 110 to 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.1 to 11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      6 to 12 years of age: 100 to 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      13 to 19 years of age: 90 to 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5 to 8.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age-specific goals for blood glucose before meals are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;6 years of age: 100 to 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      6 to 12 years of age: 90 to 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5 to 10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      13 to 19 years of age: 90 to 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5 to 7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glycemic control can be achieved in pediatric patients. This was illustrated in a single-center study of 455 pediatric patients (&lt;18 years of age) with a mean A1C level of 7.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/34\">",
"     34",
"    </a>",
"    ], in which more than two-thirds of the children met the A1C goal for glycemic control. Thirty-one percent of patients failed to meet the A1C goal of 8 percent. Multiple linear regression analysis demonstrated that lower socioeconomic status, older age, longer duration of diabetes, injection therapy (rather than insulin pump therapy), and female gender were associated with poorer glycemic control. In contrast, a larger multicenter study described poorer outcomes for glycemic control, particularly among adolescents: A1C levels were &gt;7.5 percent in more than 70 percent of adolescents, regardless of insulin regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BLOOD GLUCOSE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal glycemic control is dependent upon frequently monitoring blood glucose and appropriate adjustment of insulin dose. Ongoing monitoring allows the child and family to become familiar with the patient's glycemic response to different types and amount of foods, exercise, and stress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Insulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Frequent monitoring has been shown to improve glycemic control in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] and decrease the frequency of severe hypoglycemic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/38\">",
"     38",
"    </a>",
"    ]. Children and their parents show poor ability to detect high or low blood glucose levels based on symptoms alone. In a study that compared self-reporting of hypoglycemia with glucose meter results, children (aged 6 to 11 years) and their parents failed to detect about half of the episodes of clinically significant hypoglycemia (&lt;55",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/39\">",
"     39",
"    </a>",
"    ]. Therefore, blood glucose monitoring is essential to avoid severe hypoglycemia and to optimize blood glucose control. Generally, the frequency of self-monitoring of blood glucose (SMBG) is highest in children under the age of six years and decreases with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/37\">",
"     37",
"    </a>",
"    ]. Predictors of lower frequency of SMBG include lower self-esteem, high stress life events, and inadequate parental support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/40\">",
"     40",
"    </a>",
"    ]. Psychosocial support and parental supervision may help optimize the frequency of SMBG in older children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fingersticks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ADA recommends testing of blood glucose at least four times a day, more frequent monitoring may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. This is especially true in very young children who are at increased risk for severe hypoglycemia, and in patients who are treated with intensive therapy who have multiple meals and snacks during the day and require blood glucose checks prior to administration of a pre-meal bolus of insulin. To safeguard against hypoglycemia, monitoring at anticipated peaks of insulin action and during periods of increased physical activity may be necessary. (See",
"    <a class=\"local\" href=\"#H11299132\">",
"     'Value of an intensive regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children, blood glucose meters, which require a small sample of blood (0.3 to 1 microliter) obtained by fingerstick, are used to intermittently monitor blood glucose concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Continuous glucose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous glucose sensors that continuously measure interstitial fluid glucose levels are now available and approved for use in children. The currently available continuous monitoring systems are expensive and relatively inaccurate in the lower (&lt;70",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    glucose range, limiting their usefulness. The experience with these devices in adults is discussed separately. The advantages and disadvantages of continuous glucose monitoring systems, and the experience with these devices in adults are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first generation of continuous glucose monitors provided blood glucose data only after downloading by the physician, and did not provide real-time feedback to the patient. This type of device did not appear to improve glycemic control in children, although there was some educational value in detecting patterns of blood glucose fluctuations and episodes of hypoglycemia during periods of sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The newer generation of continuous monitors report blood glucose levels to the patient in real time. Short-term studies indicate clinical benefits of these devices as compared to conventional methods of blood glucose monitoring, when used by motivated and well-informed patients. These devices do not directly control insulin administration, but provide glucose readings to permit finer control of insulin administration by patients and their families, as demonstrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled study comparing continuous glucose monitoring versus conventional home glucose monitoring reported a significant decrease in glycated hemoglobin levels in adults using the continuous glucose sensor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/42\">",
"       42",
"      </a>",
"      ]. This benefit was not seen in children and adolescents overall, but analysis of the subgroup between 8 and 14 years old indicated that more children who used the continuous glucose sensor had a &gt;10 percent reduction in glycated hemoglobin levels and had A1C levels &lt;7 percent at 26 weeks, as compared with children using conventional blood glucose monitoring. These benefits were not observed in adolescents older than 14 years. There was no difference between groups in the number of episodes of severe hypoglycemia in any age group. This type of continuous glucose monitor also improved patient satisfaction because of increasing awareness of trends of rising or falling glucose levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in 156 children and adolescents compared insulin pump therapy used with a continuous glucose monitoring device (sensor-augmented insulin pump) with multiple daily injections (MDI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. After one year of treatment, subjects using the sensor-augmented pump reduced their glycated hemoglobin levels by 0.6 percentage points as compared with those using MDI, and 44 percent reached target glycated hemoglobin levels for their age, as compared to 20 percent in the group using MDI. Rates of severe hypoglycemia were similar between the two groups (7 events among 78 subjects using the insulin pump, versus 4 events among 81 subjects using MDI, p=0,53). Similar findings were seen in adults enrolled in the same study. However, a large number of children enrolled in these trials were unable or unwilling to continue to use the sensors during the course of the trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. An update from the STAR 3 study reported that children compared with adolescents wore the continuous glucose monitoring sensors more often and were more likely to achieve age-specific HbA1C target values. This report confirmed a reduction in HbA1C levels in the sensor group and also reported fewer hyperglycemic excursions and lower glycemic variability in this group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in 160 children and adolescents that compared the sensor-augmented insulin pump with conventional SMBG and the insulin pump reported no differences in HbA1C levels after a year between the groups. However, HbA1C levels were lower in children who used the sensor regularly versus those who used the sensor infrequently or not at all. Additionally, the sensor group had lower glycemic variability and higher C-peptide concentrations at the conclusion of the study. The sensor group had no episodes of severe hypoglycemia compared with four such episodes in the conventional SMBG-pump group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sensor-augmented pump therapy may be difficult to sustain indefinitely, and studies are ongoing to determine the optimal sampling interval that reflects long-term blood glucose control. One study indicates that a 15 day sampling period correlates well with three months of blood glucose data (r",
"    <sup>",
"     2",
"    </sup>",
"    0.66 - 0.75) in contrast to a three day sampling period, which shows weaker correlations (r",
"    <sup>",
"     2",
"    </sup>",
"    0.32 - 0.47) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/51\">",
"     51",
"    </a>",
"    ]. More studies are necessary to confirm these findings. &nbsp;",
"   </p>",
"   <p>",
"    Studies are currently evaluating the efficacy of a fully automated closed loop system of insulin delivery based on continuous glucose sensing, sometimes known as an &ldquo;artificial pancreas.&rdquo; One small short-term study reported near-normal glucose levels with the use of such a system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/52\">",
"     52",
"    </a>",
"    ], and another reported reduction in nocturnal hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/53\">",
"     53",
"    </a>",
"    ]. Trials of this type of system in adults and children are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link&amp;anchor=H15#H15\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Advantages'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INSULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous administration of insulin is designed to replace the deficient hormone and to attain normoglycemia. However, this goal remains elusive because of the difficulty in replicating the minute-to-minute variations of physiologic insulin secretion and the difference in delivery of exogenous insulin action either subcutaneously or intravenously compared to normal secretion of endogenous insulin directly into the portal vein. The failure of exogenous insulin to completely mimic physiologic insulin secretion results in acute and chronic complications of diabetes.",
"   </p>",
"   <p>",
"    There are many different insulin preparations and delivery systems available. The selected regimen is individualized for the child and family to fit their lifestyle and optimize compliance while providing glycemic control that meets age-specific goals. Input from the patient, if age appropriate, and the family (eg, timing of meals and snacks,",
"    <span class=\"nowrap\">",
"     school/daycare,",
"    </span>",
"    physical activity) is important to ensure optimal glycemic control and minimize episodes of hypoglycemia. As a result, the types of insulin and regimens used will vary among children and can change for an individual child over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin types can be classified by their onset and duration of action (",
"    <a class=\"graphic graphic_table graphicRef61880 \" href=\"mobipreview.htm?17/55/18300\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid-acting (eg, lispro, aspart, glulisine) and short-acting types (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/44/36551?source=see_link\">",
"       regular insulin",
"      </a>",
"      ) are typically administered as a premeal bolus (typically 5 to 15 minutes before the meal for the rapid-acting insulins, and 20 to 30 minutes before meals for the short-acting type) based on (i) carbohydrate content of food and (ii) the blood glucose level. If necessary, rapid-acting insulin can be administered after the meal in younger children in whom intake is unpredictable. Rapid- and short-acting insulins delivered by continuous subcutaneous infusion via an insulin pump provide basal insulin levels. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Insulin pump'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Intermediate-acting NPH insulin is usually given two or three times a day, but may be given in a targeted manner in combination with long-acting insulins. Intermediate-acting insulin thus provides some coverage for meals (eg, NPH insulin given before breakfast will cover lunch).",
"     </li>",
"     <li>",
"      Long-acting insulin preparations (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/41/18070?source=see_link\">",
"       insulin detemir",
"      </a>",
"      ) are given once or twice a day. They provide a basal insulin level that suppresses hepatic glucose production and maintains near-normal glucose levels in the fasting state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approximate time of onset, peak activity, and duration of action of the most commonly used insulins are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef61880 \" href=\"mobipreview.htm?17/55/18300\">",
"     table 5",
"    </a>",
"    ). A more complete discussion on insulin preparations is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link&amp;anchor=H5#H5\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Choice of insulin regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin is administered by needle and syringe, pen, or pump. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Insulin pump'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Needle and syringe &mdash; An advantage of needle and syringe is that NPH and short- or rapid-acting insulins can be mixed in a single injection, thereby reducing the number of injections. However,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      cannot be mixed with any other form of insulin and must be administered separately. The smallest needle available is 31 gauge and",
"      <span class=\"nowrap\">",
"       5/16",
"      </span>",
"      inches in length. Syringes are available in 30 (0.3 mL), 50 (0.5 mL), and 100 (1 mL) unit sizes. Thirty unit syringes marked to administer half units are available.",
"     </li>",
"     <li>",
"      Pens &mdash; Pens are supplied pre-filled with insulin and may be either disposable or reusable. The ease of use and portability of pens are appealing to many patients. The smallest needle available is 32 gauge and 4 or 5 mm in length. Although mixed insulin preparations are available in pens, these are not tailored to the needs of children. Mixed insulin pens are usually reserved for individuals who are limited in their ability to make dosing decisions and, as a result, glycemia is not usually as strictly controlled. Pens that deliver aspart and lispro insulin are available that offer the flexibility of half-unit delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11299132\">",
"    <span class=\"h2\">",
"     Value of an intensive regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of insulin regimens are available to children with diabetes and their families:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional regimen &mdash; This traditional therapy includes administration of an intermediate-acting insulin (NPH) at least twice a day (at breakfast and a second dose either at dinner or bedtime), with a rapid-acting (ie, lispro or aspart) or short-acting (\"regular\") insulin two or three times a day. The rapid- or short-acting insulin would be given at breakfast and dinner, and sometimes at lunch or with the afternoon snack depending on blood glucose concentrations. This regimen is fixed and the patient and family must adjust their lifestyles so that meals and vigorous physical activity occur on a relatively fixed daily schedule. Two-thirds of the total daily dose is administered before breakfast",
"      <span class=\"nowrap\">",
"       (2/3",
"      </span>",
"      as NPH and",
"      <span class=\"nowrap\">",
"       1/3",
"      </span>",
"      as rapid- or short-acting insulin) and one-third before dinner and at bedtime",
"      <span class=\"nowrap\">",
"       (1/3",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      as rapid- or short-acting insulin before dinner and",
"      <span class=\"nowrap\">",
"       2/3",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      as NPH at bedtime). The dose of NPH can be split such that a portion is delivered before dinner and the remainder at bedtime.",
"     </li>",
"     <li>",
"      Intensive regimens &mdash; An intensive regimen provides insulin in a manner that more closely approaches physiologic insulin secretion than does conventional therapy. It includes administration of an insulin preparation that will maintain a basal insulin level and suppress lipolysis and hepatic glucose production, with additional pre-meal and pre-snack boluses of rapid- or short-acting insulin to minimize postprandial elevation of blood glucose. These boluses are adjusted according to the carbohydrate content of meals as well as the current blood glucose level. This approach allows greater flexibility than the conventional regimen in terms of timing and carbohydrate content of meals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults, controlled studies, such as the Diabetes Control and Complications Trial (DCCT), have demonstrated that intensive insulin therapy achieved better glycemic control and reduced the incidence of long-term sequelae, as compared to conventional insulin therapy (which utilized one or two fixed insulin injections, including mixtures of insulin) (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"mobipreview.htm?28/32/29197\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73143 \" href=\"mobipreview.htm?18/21/18781\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Controlled studies in adolescents show similar improved glycemic control with intensive as compared to conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. As an example, a sub-set analysis of 195 adolescents (13 to 17 years of age), who participated in DCCT, demonstrated that intensive compared to conventional therapy improved glycemic control and decreased the risk of retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/55\">",
"     55",
"    </a>",
"    ]. Results are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intensive compared to conventional therapy decreased the mean daily blood glucose level (177 &plusmn; 31 versus 260 &plusmn; 52",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Median A1C levels throughout the study were significantly lower with intensive therapy.",
"     </li>",
"     <li>",
"      Intensive therapy decreased the risk of retinopathy (RR 0.53, 95% CI 0.1 to 0.78).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies have also reported improved glycemic control in children (age range from 1.9 to 19.6 years) with intensive compared to conventional insulin regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the choice of regimen depends upon patient, family, and clinician preference, we recommend that an intensive regimen be selected whenever possible based upon the above data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11299231\">",
"    <span class=\"h2\">",
"     Types of intensive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intensive regimen is delivered either by multiple daily injections, or by continuous insulin infusion (pump). The choice of intensive regimen is based upon patient, family, and clinician preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Multiple daily injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multiple daily injections (MDI) regimen combines a baseline level of insulin using a long-acting insulin analog (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or detemir) with",
"    <span class=\"nowrap\">",
"     premeal/snack",
"    </span>",
"    boluses of rapid- or short-acting insulin. This approach results in more stable glycemic control and fewer episodes of hypoglycemia than the conventional approach in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/54,56,57\">",
"     54,56,57",
"    </a>",
"    ]. This was illustrated in a controlled cross-over trial of 28 adolescents with type 1 diabetes that compared MDI using insulin glargine and lispro to conventional therapy using NPH and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/44/36551?source=see_link\">",
"     regular insulin",
"    </a>",
"    during two 16-week study periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/54\">",
"     54",
"    </a>",
"    ]. Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MDI compared to conventional therapy resulted in lower mean fasting; pre- and post-breakfast, and pre- and post-lunch blood glucose levels. There were no differences in pre- and post-dinner blood glucose levels.",
"     </li>",
"     <li>",
"      Although not statistically significant, there was a trend toward lower A1C levels with MDI (8.7 versus 9.1 percent).",
"     </li>",
"     <li>",
"      The incidence of nocturnal hypoglycemia was lower with MDI. There was no difference in the incidence of self-reported symptomatic hypoglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pre-meal and pre-snack bolus doses of a rapid- or short-acting insulin are based upon three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premeal blood glucose level",
"     </li>",
"     <li>",
"      Estimated amount of carbohydrates to be consumed",
"     </li>",
"     <li>",
"      Expected level of exercise after the meal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"     Insulin glargine",
"    </a>",
"    is the long-acting analog most commonly used in pediatric patients. It usually has a duration of action of 20 to 24 hours, but the half-life is shorter in some patients, requiring division of the daily dose into two injections per day.",
"   </p>",
"   <p>",
"    Although the United States Food and Drug Administration (FDA) has only approved",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"     insulin glargine",
"    </a>",
"    in children &ge;6 years of age, the use of insulin glargine appears to be beneficial in younger children as well. Observational studies in children &lt;6 years of age have shown that the use of insulin glargine reduced the incidence of severe hypoglycemic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/60-62\">",
"     60-62",
"    </a>",
"    ] and improved glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In a controlled cross-over trial of 28 adolescents with type 1 diabetes, use of insulin glargine and lispro resulted in a reduced incidence of nocturnal hypoglycemia compared to use of conventional therapy with NPH and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/44/36551?source=see_link\">",
"     regular insulin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/54\">",
"     54",
"    </a>",
"    ]. These results are probably due to the increased flexibility of this regimen in young children who have unpredictable patterns of meal intake and variable levels of physical exercise.",
"   </p>",
"   <p>",
"    MDI using glargine in this age group should be carried out under the supervision of an experienced pediatric diabetes team. Studies have explored the possibility of an association between the use of glargine, which has a modified structure similar to IGF-1, and risk of malignancy. The results are not conclusive, and most experts feel that this is not a concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many families choose this regimen because of its increased flexibility, MDI requires increased blood glucose monitoring and increased frequency of insulin administration. The patient and family also are required to count dietary carbohydrates and accurately judge the impact of exercise on insulin requirements. Without this increased involvement and",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    education, the benefits of this regimen are not attained. Before initiation of MDI, the patient and family must understand and accept the increased commitment and the need for increased frequency of blood monitoring and insulin injections required by this therapeutic approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Insulin pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin pump (continuous subcutaneous insulin infusion) is increasingly used in the pediatric population. In 2006, there were more than 35,000 patients younger than the age of 21 years who received insulin therapy through a pump system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/64\">",
"     64",
"    </a>",
"    ]. A position statement of the ADA, European Society for Pediatric Endocrinology and others recommends that insulin pump therapy should be considered for patients with one or more of the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent severe hypoglycemia",
"     </li>",
"     <li>",
"      Wide fluctuations in blood glucose levels (regardless of A1C)",
"     </li>",
"     <li>",
"      Suboptimal diabetes control (A1C exceeds target range for age)",
"     </li>",
"     <li>",
"      Microvascular complications",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      risk factors for macrovascular complications",
"     </li>",
"     <li>",
"      Good metabolic control, but insulin regimen that compromises lifestyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other situations in which the insulin pump may be helpful include young children and infants, adolescents with eating disorders, pregnant adolescents, ketosis-prone individuals, and competitive athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin pumps deliver a basal rate (small aliquots every few minutes, evenly spaced over an hour) of either rapid- or short-acting insulin subcutaneously. The rate of insulin administration can be transiently increased to give mealtime or glucose correction boluses. Most insulin pump therapy is now started with a rapid-acting insulin, rather than short-acting insulin.",
"    <span class=\"nowrap\">",
"     Pre-meal/snack",
"    </span>",
"    boluses are administered to minimize increases in postprandial glucose concentrations. Insulin is delivered through a subcutaneously inserted catheter that is replaced at two- to three-day intervals. Information on insulin administration, frequency of catheter site changes, and frequency and timing of premeal insulin boluses can be downloaded from a memory chip within the pump. Insulin pumps have not yet incorporated a \"closed loop\" system in which blood glucose values are determined and automatically used to reprogram the insulin pump. Therefore, insulin pump therapy relies on frequent blood glucose monitoring and appropriate readjustment of insulin infusion rates either by the patient or parent.",
"   </p>",
"   <p>",
"    Data from controlled studies in adults demonstrate the superiority of intensive therapy compared with conventional therapy in achieving glycemic control and reducing the incidence of long-term sequelae. In addition, one meta-analysis has reported that continuous insulin infusion (pump therapy) appears to provide slightly better glycemic control and decreased hypoglycemia than MDI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link&amp;anchor=H12#H12\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Continuous subcutaneous insulin infusion (insulin pump)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children and adolescents, observational studies reported improved glycemic control and fewer episodes of hypoglycemia with pump insulin administration compared with previous insulin regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/58,66-72\">",
"     58,66-72",
"    </a>",
"    ]. Previous regimens included conventional therapy in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/58\">",
"     58",
"    </a>",
"    ] and MDI in three other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/66,70,71\">",
"     66,70,71",
"    </a>",
"    ]. In the remaining three studies, it is unclear what previous regimen was used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Beneficial use of insulin pump therapy has been reported in children as young as 2 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/58,70,73,74\">",
"     58,70,73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpretation of these results should consider that patients and families who were selected for insulin pump therapy were self-selected (expressed an interest in pump therapy), received additional training (ie, use of insulin pump, carbohydrate counting, and the use of an insulin to carbohydrate ratio), and had more frequent follow-up visits, all of which would be expected to have a beneficial effect on blood glucose control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small controlled trials comparing the insulin pump to MDI have shown no difference in glycemic control and frequency of hypoglycemic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/64,73,76-78\">",
"     64,73,76-78",
"    </a>",
"    ]. The pump appears to be both safe and effective, although it is unclear whether it improves diabetes control compared with other insulin delivery systems in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/79\">",
"     79",
"    </a>",
"    ]. The following reports describe some of the beneficial effects of insulin pump therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial of 32 children demonstrated that insulin pump therapy compared to MDI resulted in lower A1C levels (7.2 versus 8.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of six randomized controlled trials revealed lower glycated hemoglobin levels and reduction of daily insulin doses in children using the insulin pump as compared with those using MDI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis reported a reduction in severe hypoglycemia in patients using the insulin pump compared with MDI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insulin pump therapy has also been used in conjunction with a continuous glucose monitoring device to give the patient more information about their blood glucose levels and allow them to make better-informed decisions about insulin dosing; this approach is known as sensor-augmented insulin pump therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Continuous glucose monitoring'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin pump therapy is often preferred by children and their families. MDI regimens can require as many as six to seven injections per day, which may be a barrier for some patients and families. An insulin pump can be an attractive option for intensive therapy at any age, and appears to improve quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/73,74,83,84\">",
"     73,74,83,84",
"    </a>",
"    ]. Of note, most families with young children who participated in clinical studies decided to continue with pump therapy even after the study was completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many families choose the insulin pump because of its increased flexibility, particularly with regards to meals and socialization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/85\">",
"     85",
"    </a>",
"    ], but similar to MDI therapy, continuous insulin infusion therapy requires increased blood glucose monitoring, counting dietary carbohydrates, judging the impact of exercise on insulin requirements, and making the appropriate adjustments to insulin infusion rates. Without this increased commitment, the benefits of this regimen are not attained. Before initiation of insulin pump therapy, the patient and family must be informed and accept the increased work required by this therapeutic approach. The beneficial effect of the insulin pump is maintained only if the child and family continue to devote time to carbohydrate counting and determining appropriate insulin boluses at mealtime.",
"   </p>",
"   <p>",
"    Other considerations regarding the choice of regimen include the greater cost of the pump and its supplies compared to those of syringes and needles used in MDI therapy, as well as the complications of pump therapy, such as infusion pump failure, superficial infection, and minor dermatologic changes such as nodules or scars at the catheter site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/68,86\">",
"     68,86",
"    </a>",
"    ]. Because rapid- or short-acting insulin is used alone in insulin pumps and patients have no long-acting subcutaneous depot of insulin, pump failure can result in rapid onset of diabetic ketoacidosis. This is another reason why frequent blood glucose checking is mandated in children on insulin pump therapy.",
"   </p>",
"   <p>",
"    Although multiple studies have demonstrated an improvement of diabetes control with the insulin pump compared with MDI, decreased adherence to the pump protocol can occur over time and is associated with deterioration in control. Parental involvement during this time may help offset this risk in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin requirement is based upon the body weight, age, and pubertal stage of the child. In general, the newly diagnosed child requires an initial total daily insulin dose of 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     units/kg.",
"    </span>",
"    Prepubertal children usually require lower doses, and the dose requirement may be as low as 0.25",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    for a variable period following diagnosis. Higher doses are needed in pubertal children, patients in ketoacidosis, or in patients receiving glucocorticoid therapy. &nbsp;",
"   </p>",
"   <p>",
"    In infants and toddlers who receive their insulin by syringe, the insulin dose may be so small that dilution is required to allow for easier and more precise administration. The smallest dose of insulin that can be accurately administered without dilution using a syringe is 0.5 units. Many insulins can be diluted either at a specialized pharmacy or at home with proper training. Specific diluent for many insulin preparations is available from the insulin manufacturer. Some insulin pumps can deliver much smaller doses of insulin, of the order of 0.025 units at a time, often obviating this problem.",
"   </p>",
"   <p>",
"    Follow-up visits at least every three months are required to adjust for the increasing insulin requirement with continued growth of the child and increasing insulin deficiency with duration of diabetes. The family can be taught to make interim adjustments via telephone consultation. As a child enters puberty, daily insulin requirements may increase to more than 1",
"    <span class=\"nowrap\">",
"     unit/kg",
"    </span>",
"    because puberty increases insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Balance of insulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;To use the different types of insulin in intensive therapy, the various functions of exogenous insulin need to be considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basal insulin &mdash; In children, the basal insulin requirement (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      or basal rate of pump) usually is approximately 40 to 50 percent of the total daily dose.",
"     </li>",
"     <li>",
"      Correction of elevated blood glucose &mdash; An insulin correction factor can be used to select an insulin dose to correct hyperglycemia before meals or between meals. For rapid-acting insulin, divide 1500 by the total daily insulin dose. This calculation estimates the decrease in blood glucose from one unit of a rapid-acting insulin. As an example, if the total daily insulin dose is 30 units, then 1 unit of rapid-acting insulin will decrease the blood glucose approximately by 50",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Utilization of ingested carbohydrate &mdash; A rapid-acting insulin pre-meal or pre-snack is used to provide the insulin requirements for the anticipated consumption of carbohydrates. The amount of ingested carbohydrate covered by one unit of rapid-acting insulin is roughly calculated based upon the total daily insulin dose and dividing this into 500. As an example, if the total daily insulin dose is 50 units, then 1 unit of rapid-acting insulin will cover 10 grams of carbohydrate. For short-acting (regular) insulin (rarely used in MDI or pump regimens), divide 450 by the total daily insulin dose. However, there is a wide range of insulin to carbohydrate ratios, with more insulin being required in older children and less in younger children than indicated by these calculations.",
"      <br/>",
"      <br/>",
"      On average, 1 unit of insulin is required to cover:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      20 grams of carbohydrates in most young children (1 to 6 years of age)",
"     </li>",
"     <li>",
"      10 to 12 grams of carbohydrates in older prepubertal children",
"     </li>",
"     <li>",
"      8 to 10 grams in pubertal adolescents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When converting a patient from MDI or conventional therapy to insulin pump, the initial dose is dependent on diabetes control and total daily insulin dose. If control has been excellent, the initial daily insulin pump dose is 10 to 20 percent less than the previous dose. If control has been poor, the same total previous daily dose should be used. One study suggests patients using detemir insulin may require greater dose reductions (26 to 33 percent) when switching from MDI to the insulin pump [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous glucose monitoring using a subcutaneous sensor may be particularly useful for selected highly-motivated patients using intensive insulin therapy and to reduce the risk of hypoglycemia. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Continuous glucose monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Honeymoon phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few weeks after the diagnosis and initiation of insulin therapy, a period of decreasing exogenous insulin requirement occurs, commonly referred to as the \"honeymoon\" or remission phase of diabetes. During this period, the remaining functional beta cells secrete some endogenous insulin resulting in reduced exogenous requirement. Close monitoring of blood glucose is mandatory as hypoglycemic episodes are likely if the insulin dose is not appropriately adjusted. The duration of this phase is variable and may last several months to several years. Rising blood glucose levels, A1C, and increasing exogenous insulin need indicates the end of this phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10801887\">",
"    <span class=\"h1\">",
"     NEWER THERAPIES FOR TYPE 1 DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of attempts to use immune modulation early in the course of type1 diabetes have been reported, but long-term success is elusive as yet. These include trials of a vaccine against glutamic acid decarboxylase (GAD),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    , teplizumab, and other immunomodulators for patients with newly diagnosed diabetes, the details of which are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Immunomodulators'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Multidrug therapy with agents like",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/59/13238?source=see_link\">",
"     metformin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    -like peptide 1 (GLP-1) receptor agonists have not yet been proven more effective than insulin alone for children with type 1 diabetes. &ldquo;Closed loop&rdquo; insulin pump devices, which deliver insulin based on real time glucose concentrations and are controlled by a computer driven algorithm, are currently in active development. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Insulin pump'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other issues that need to be addressed in the management of children and adolescents with type 1 diabetes include nutrition, exercise, and psychosocial factors that impact on glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescriptive nutritional therapy depends in large part on the choice of insulin regimen. Ideally, meal planning should provide a consistent carbohydrate intake. This is especially true for children on a conventional fixed insulin regimen who require a nutritional prescription. Meal planning must be individualized to accommodate the child's food preference and cultural eating patterns and schedules.",
"   </p>",
"   <p>",
"    At the time of diagnosis, many patients have lost weight that is restored with the initiation of insulin therapy, hydration, and adequate energy intake. During this time of increased consumption, children often require large amounts of insulin to control their blood glucose levels. After correction of weight loss in a few weeks, ongoing assessment of growth (eg, weight, height, body mass index [BMI]) is necessary to monitor adequacy of dietary intake and glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/90\">",
"     90",
"    </a>",
"    ]. Excellent glycemic control is necessary for normal growth and development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/91\">",
"     91",
"    </a>",
"    ]. Excess insulin administration, or failure to reduce insulin dose post puberty or after initial regain of weight, may lead to excessive weight gain as the child attempts to treat hypoglycemia by overeating. If the child becomes overweight, caloric intake or insulin administration may need to be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is desirable for the patient and family to consult with a registered dietitian with experience in pediatric nutrition and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"     4",
"    </a>",
"    ]. The dietitian provides instruction regarding the effect of food on blood glucose concentration, a diet that ensures adequate nutritional intake, and information regarding carbohydrate counting. Mastery of carbohydrate counting and understanding the glycemic effects of different kinds of carbohydrates is especially important in patients on an intensive regimen, who need to adjust pre-meal boluses insulin based upon the anticipated glycemic effect of consumed carbohydrates. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Balance of insulins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nutrition management including consistency of carbohydrate intake, carbohydrate counting, and glycemic content and index is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with diabetes, the physiologic response to exercise depends upon the plasma insulin concentration at the time of exercise. This variable response increases the risk of hypoglycemia in patients when they engage in physical activity that is greater in intensity, duration or frequency than normal activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who participate in sport activities require increased monitoring of blood glucose (before, after, and hourly during prolonged strenuous activity) and appropriate adjustment of insulin dosing. Afternoon or evening exercise may cause hypoglycemia later that night.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children on fixed-dose insulin regimens, snacks should be administered before sports. Some children may require additional carbohydrates after sports because intense physical exertion can result in high blood glucose during sports, likely from increased catecholamine release, but will usually result in hypoglycemia later if not treated following the physical activity.",
"     </li>",
"     <li>",
"      In children on insulin pump therapy, the basal insulin infusion rate is reduced by 30 to 70 percent during sports activities to prevent hypoglycemia. Some children on pump therapy benefit from decreasing their daily basal insulin infusion rate by half and receiving the other half as an injection of a long-acting insulin (glargine) once daily to replace half the basal received by pump. This allows the child to disconnect the pump during periods of exercise without loss of glycemic control. This approach may be particularly helpful during the summer if the child is swimming frequently or heavily involved in sports activities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    School personnel and coaches need to recognize symptoms of hypoglycemia and know how to treat hypoglycemia. At the onset of a new sports season, frequent blood glucose monitoring during the 12 hours after physical activity should be performed to guide insulin dose adjustment as insulin requirements will decrease during this period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=see_link&amp;anchor=H5#H5\">",
"     \"Special situations in children and adolescents with type 1 diabetes mellitus\", section on 'School and daycare'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes, as with other chronic diseases, has a psychological impact on the patient and family. Depression and anxiety are common in parents, older children, and adolescents with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/17,18,92,93\">",
"     17,18,92,93",
"    </a>",
"    ], and adolescents are at risk for an eating disorder. In older children and adolescents, family conflict arises over the level of adult involvement in the care of the patient during a normal developmental period of increasing independence and self-assertiveness. These psychological issues lead to poorer glycemic control and an increased risk of hospitalization and episodes of diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adolescents'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, socioeconomic factors such as single-parent families, poor socioeconomic status, ethnicity, and chronic physical or mental health problems in a parent or other close family member are associated with poorer diabetes control and increased hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4,94,97\">",
"     4,94,97",
"    </a>",
"    ]. One study from New Zealand reported that Maori or Pacific ethnicity and social deprivation are independent predictors of poor metabolic control in type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comprehensive management of diabetes that addresses these psychosocial issues can improve glycemic control and reduce hospitalization even in the high-risk adolescent. In two controlled studies, structured psychoeducational support significantly improved glycemic control and reduced hospital admission rates in previously poorly controlled adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Additionally, psychological screening of newly diagnosed patients with type 1 diabetes may help identify families at risk for poor adherence and poor diabetes control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H17#H17\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Psychiatric disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors associated with better health related quality of life in children and adolescents with diabetes include later age at onset, fewer hyperglycemic episodes, lower HbA1C, older age, and the male gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8539070\">",
"    <span class=\"h2\">",
"     Parental and caregiver involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study reported that an authoritative parenting style was an important determinant of diabetes control in children, and paternal involvement was important for diabetes management in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/101\">",
"     101",
"    </a>",
"    ]. Parental \"burn-out\" can thus increase the risk for poor control, and predictors of burnout in a parent include low self esteem, inadequate social support, high need for control, lack of leisure time, financial concerns, and the perception that the child's disease affects everyday life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/102\">",
"     102",
"    </a>",
"    ]. In addition, adolescents who perceive greater sharing of responsibility for diabetes care with their caregivers are more likely to engage in better management of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/103\">",
"     103",
"    </a>",
"    ]. One study reported an improvement in HbA1C levels and an improvement in quality of life responses in adolescents with type 1 diabetes who chose to participate in physician moderated chat sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/9/40090/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes should be given the following immunizations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All standard childhood immunizations, on a standard schedule (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"       \"Standard immunizations for children and adolescents\", section on 'Overview'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Annual influenza vaccine (also recommended for all individuals 6 months of age and older). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumococcal vaccine. Children with diabetes should receive the pneumococcal conjugate vaccine, which is recommended for all children. They should also be given the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      , because they are considered to be at high risk for invasive pneumococcal disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence for an association between immunizations and the development of type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=see_link&amp;anchor=H12#H12\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\", section on 'Type 1 diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequency of follow-up visits is tailored to the needs of the child and family. Visits are more frequent during the initial educational phase with intensive training in self-care management for the family and during periods when adjustment of glycemic control and insulin dose are problematic. More frequent visits are also necessary when major changes in insulin regimen are made (eg, commencing insulin pump therapy).",
"   </p>",
"   <p>",
"    Once the family is well trained and a management plan is established and stable, we recommend follow-up at least every three months to review glycemic control and adjust management as needed. However, families must be trained to perform interim adjustments and to contact the diabetes team for assistance in adjustment of insulin dosing between visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14093656\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed at least twice a year and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Height and weight &mdash; Monitor for normal growth and weight gain",
"     </li>",
"     <li>",
"      Blood pressure &mdash; Screen for hypertension",
"     </li>",
"     <li>",
"      Pubertal assessment &mdash; Because puberty increases insulin resistance, increased insulin requirement can be anticipated by identifying early signs of puberty",
"     </li>",
"     <li>",
"      Thyroid &mdash; Check for thyroid enlargement to screen for autoimmune hypothyroidism, an associated condition of type 1 diabetes (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=see_link&amp;anchor=H3#H3\">",
"       \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\", section on 'Autoimmune thyroiditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin &mdash; Examination of injection sites for evidences of lipohypertrophy or atrophy that can alter insulin absorption rates",
"     </li>",
"     <li>",
"      Eyes &mdash; Funduscopic examination without dilation of the pupils is of little value as a screen for retinopathy because diabetic retinopathy usually starts at the periphery of the retina; all patients should have regularly scheduled dilated funduscopic examinations, as discussed below.",
"     </li>",
"     <li>",
"      Extremities &mdash; As the disease duration increases, extremity examination for evidence of limited joint mobility (sclerodactyly, joint or finger stiffness) or peripheral neuropathy (feet). A foot examination should be performed annually in children &ge;10 years of age. (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=see_link\">",
"       \"Musculoskeletal complications in diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=see_link\">",
"       \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14093663\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation includes evaluation of glycemic control and screening for long-term sequelae:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A1C, to evaluate glycemic control &mdash; perform every three months",
"     </li>",
"     <li>",
"      Urine testing for microalbuminuria, to screen for nephropathy &mdash; perform annually for children &ge;10 years of age with a five-year duration of diabetes",
"     </li>",
"     <li>",
"      Celiac disease screening &mdash; perform at diagnosis and every other year",
"     </li>",
"     <li>",
"      Lipid profile, to screen for dyslipidemia (as recommended in the ADA guidelines (",
"      <a class=\"graphic graphic_table graphicRef75008 \" href=\"mobipreview.htm?34/21/35164\">",
"       table 6",
"      </a>",
"      )) &mdash; perform once puberty begins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If results are normal, repeat the screen every five years",
"     </li>",
"     <li>",
"      If results are abnormal, screen annually",
"     </li>",
"     <li>",
"      Rescreen at the time of a prolonged episode of poor glycemic control, because children who are in poor glycemic control may manifest new lipid abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid function testing, to screen for autoimmune hypothyroidism &mdash; perform very one or two years or if features of hypothyroidism or if an enlarged thyroid are evident",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details about the screening for these and other complications and associated conditions (eg, nephropathy, retinopathy, celiac disease, dyslipidemia, autoimmune thyroiditis) are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=see_link\">",
"     \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14093670\">",
"    <span class=\"h3\">",
"     Referrals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referrals include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nutrition therapy by registered dietitian",
"     </li>",
"     <li>",
"      Mental health evaluation including screening for depression for children &ge;10 years of age",
"     </li>",
"     <li>",
"      Dilated ophthalmologic evaluation for retinopathy yearly for children &ge;10 years of age or after five-year duration of diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Special situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special situations such as illness, travel, and medical and dental procedures (eg, endoscopy, surgery), which require adjusting diabetes management, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=see_link\">",
"     \"Special situations in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"       \"Patient information: My child has diabetes: How will we manage? (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=see_link\">",
"       \"Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=see_link\">",
"       \"Patient information: Carb counting and your child&rsquo;s diet (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/11/38066?source=see_link\">",
"       \"Patient information: Managing diabetes in school (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"       \"Patient information: Giving your child insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/26/39331?source=see_link\">",
"       \"Patient information: Checking your child&rsquo;s blood sugar level (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/47/6899?source=see_link\">",
"       \"Patient information: Should I switch to an insulin pump? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of a child with diabetes is defined by the implementation of a care plan that maintains glucose control as near to normal as safely possible, balancing the risks of long-term sequelae and hypoglycemia. This requires comprehensive case management and intensive training of the patient and family. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Goals'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes education and self-management training by a pediatric diabetes multidisciplinary team provides the ideal setting to acquire the knowledge and skills needed for care. Training is divided into an initial and ongoing management phase. In the initial phase, the team teaches the family about the disease process and skills required for daily care (administering insulin, blood glucose monitoring, testing for urine ketones, and recognizing and treating hypoglycemia) (",
"      <a class=\"graphic graphic_table graphicRef71840 \" href=\"mobipreview.htm?18/29/18909\">",
"       table 1",
"      </a>",
"      ). In the ongoing phase, the care and training required for excellent control are reviewed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of childhood type 1 diabetes is dependent on the age of the patient, because the risk of hypoglycemia varies with age. In children with type 1 diabetes, we suggest that age-specific goals for glycemic control be used (",
"      <a class=\"graphic graphic_table graphicRef63148 \" href=\"mobipreview.htm?27/26/28076\">",
"       table 4",
"      </a>",
"      ), which are based upon the risk of hypoglycemia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Age-specific goals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Age-based care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability of the child to participate in self-management varies with the age, cognitive abilities, and emotional maturity of the child or adolescent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Age-based care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the choice of insulin regimen depends upon patient, family, and clinician preference, whenever possible we recommend that an intensive insulin regimen be selected for children with type 1 diabetes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Intensive compared to conventional therapy improves glycemic control and decreases long-term complications of diabetes. (See",
"      <a class=\"local\" href=\"#H11299132\">",
"       'Value of an intensive regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intensive insulin therapy combines the administration of a basal level of insulin together with premeal boluses of a rapid-acting insulin. This regimen is delivered by two methods: (i) multiple daily injections (injections of a long-acting insulin analog once or twice daily and rapid- or short-acting insulin before meals and snacks), and (ii) insulin pump (continuous subcutaneous delivery of a rapid- or short-acting insulin with pre-meal boluses). Both regimens require further family training, and increased family commitment and work. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Multiple daily injections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Insulin pump'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood glucose monitoring using a blood glucose meter is required for optimal glycemic control. The frequency of monitoring is dependent upon the risk of hypoglycemic episodes, the insulin regimen selected, and level of physical activity. As a minimum, monitoring should be performed four times a day. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Blood glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The impact of nutrition and exercise on insulin requirements and glycemic control should be reviewed with the patient and family. Nutritional prescriptive therapy should be developed in consultation with a registered dietitian. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Nutrition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"       \"Nutritional considerations in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with diabetes and their families are at increased risk for psychological disorders such as depression and anxiety, which result in poor glycemic control. Addressing these psychosocial issues improves glycemic control. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Psychosocial issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frequency of follow-up visits is tailored to the needs of the child and family. Follow-up visits monitor the child's glycemic control and growth with appropriate readjustments to the management plan. Ongoing visits allow for continued family education and screening for complications of diabetes. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/1\">",
"      Rewers A, Klingensmith G, Davis C, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics 2008; 121:e1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/2\">",
"      Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005; 52:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/3\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/4\">",
"      Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/5\">",
"      Beck JK, Logan KJ, Hamm RM, et al. Reimbursement for pediatric diabetes intensive case management: a model for chronic diseases? Pediatrics 2004; 113:e47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/6\">",
"      Chase HP, Crews KR, Garg S, et al. Outpatient management vs in-hospital management of children with new-onset diabetes. Clin Pediatr (Phila) 1992; 31:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/7\">",
"      Clar C, Waugh N, Thomas S. Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus. Cochrane Database Syst Rev 2003; :CD004099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/8\">",
"      Simell T, Moren R, Keltikangas-J&auml;rvinen L, et al. Short-term and long-term initial stay in hospital of children with insulin-dependent diabetes: adjustment of families after two years. Acta Paediatr 1995; 84:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/9\">",
"      Svoren BM, Butler D, Levine BS, et al. Reducing acute adverse outcomes in youths with type 1 diabetes: a randomized, controlled trial. Pediatrics 2003; 112:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/10\">",
"      Ellis DA, Frey MA, Naar-King S, et al. Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control: a randomized controlled trial. Diabetes Care 2005; 28:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/11\">",
"      Ryan CM, Becker DJ. Hypoglycemia in children with type 1 diabetes mellitus. Risk factors, cognitive function, and management. Endocrinol Metab Clin North Am 1999; 28:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/12\">",
"      Perantie DC, Lim A, Wu J, et al. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes 2008; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/13\">",
"      Social Security Administration. Revised medical criteria for evaluating endocrine disorders. Final rules. Fed Regist 2011; 76:19692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/14\">",
"      Pattison HM, Moledina S, Barrett TG. The relationship between parental perceptions of diabetes and glycaemic control. Arch Dis Child 2006; 91:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/15\">",
"      Fonagy P, Moran GS, Lindsay MK, et al. Psychological adjustment and diabetic control. Arch Dis Child 1987; 62:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/16\">",
"      Follansbee DS. Assuming responsibility for diabetes management: what age? What price? Diabetes Educ 1989; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/17\">",
"      Kovacs M, Iyengar S, Goldston D, et al. Psychological functioning of children with insulin-dependent diabetes mellitus: a longitudinal study. J Pediatr Psychol 1990; 15:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/18\">",
"      Grey M, Cameron ME, Lipman TH, Thurber FW. Psychosocial status of children with diabetes in the first 2 years after diagnosis. Diabetes Care 1995; 18:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/19\">",
"      Nassau JH, Drotar D. Social competence in children with IDDM and asthma: child, teacher, and parent reports of children's social adjustment, social performance, and social skills. J Pediatr Psychol 1995; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/20\">",
"      Cameron FJ, Northam EA, Ambler GR, Daneman D. Routine psychological screening in youth with type 1 diabetes and their parents: a notion whose time has come? Diabetes Care 2007; 30:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/21\">",
"      Seiffge-Krenke I. The highly structured climate in families of adolescents with diabetes: functional or dysfunctional for metabolic control? J Pediatr Psychol 1998; 23:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/22\">",
"      Wysocki T. Associations among teen-parent relationships, metabolic control, and adjustment to diabetes in adolescents. J Pediatr Psychol 1993; 18:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/23\">",
"      Miller-Johnson S, Emery RE, Marvin RS, et al. Parent-child relationships and the management of insulin-dependent diabetes mellitus. J Consult Clin Psychol 1994; 62:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/24\">",
"      Anderson BJ, Vangsness L, Connell A, et al. Family conflict, adherence, and glycaemic control in youth with short duration Type 1 diabetes. Diabet Med 2002; 19:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/25\">",
"      Golden MP. Incorporation of quality-of-life considerations into intensive diabetes management protocols in adolescents. Diabetes Care 1998; 21:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/26\">",
"      Laffel LM, Vangsness L, Connell A, et al. Impact of ambulatory, family-focused teamwork intervention on glycemic control in youth with type 1 diabetes. J Pediatr 2003; 142:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/27\">",
"      Peters A, Laffel L, American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). Diabetes Care 2011; 34:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/28\">",
"      Clarke WL, Cox DJ, Gonder-Frederick LA, Kovatchev B. Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes. JAMA 1999; 282:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/29\">",
"      Nakhla M, Daneman D, To T, et al. Transition to adult care for youths with diabetes mellitus: findings from a Universal Health Care System. Pediatrics 2009; 124:e1134.",
"     </a>",
"    </li>",
"    <li>",
"     National Diabetes Education Program, Transitions from pediatric to adult health care. Available at: file://ndep.nih.gov/transitions/ResourcesList.aspx (Accessed on February 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/31\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/32\">",
"      Davis EA, Keating B, Byrne GC, et al. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child 1998; 78:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/33\">",
"      Bulsara MK, Holman CD, Davis EA, Jones TW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care 2004; 27:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/34\">",
"      Springer D, Dziura J, Tamborlane WV, et al. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. J Pediatr 2006; 149:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/35\">",
"      Paris CA, Imperatore G, Klingensmith G, et al. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. J Pediatr 2009; 155:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/36\">",
"      Anderson B, Ho J, Brackett J, et al. Parental involvement in diabetes management tasks: relationships to blood glucose monitoring adherence and metabolic control in young adolescents with insulin-dependent diabetes mellitus. J Pediatr 1997; 130:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/37\">",
"      Ziegler R, Heidtmann B, Hilgard D, et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes 2011; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/38\">",
"      Haller MJ, Stalvey MS, Silverstein JH. Predictors of control of diabetes: monitoring may be the key. J Pediatr 2004; 144:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/39\">",
"      Gonder-Frederick L, Zrebiec J, Bauchowitz A, et al. Detection of hypoglycemia by children with type 1 diabetes 6 to 11 years of age and their parents: a field study. Pediatrics 2008; 121:e489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/40\">",
"      Helgeson VS, Honcharuk E, Becker D, et al. A focus on blood glucose monitoring: relation to glycemic control and determinants of frequency. Pediatr Diabetes 2011; 12:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/41\">",
"      Yates K, Hasnat Milton A, Dear K, Ambler G. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controlled trial. Diabetes Care 2006; 29:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/42\">",
"      Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/43\">",
"      Danne T, Lange K, Kordonouri O. Real-time glucose sensors in children and adolescents with type-1 diabetes. Horm Res 2008; 70:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/44\">",
"      Improving surgical outcomes with data tool. Healthcare Benchmarks Qual Improv 2008; 15:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/45\">",
"      Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/46\">",
"      Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes 2012; 13:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/47\">",
"      Diabetes Research in Children Network Study Group, Weinzimer S, Xing D, et al. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes 2009; 10:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/48\">",
"      Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther 2010; 12:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/49\">",
"      Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Buckingham B, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009; 32:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/50\">",
"      Kordonouri O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010; 53:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/51\">",
"      Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011; 13:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/52\">",
"      Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008; 31:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/53\">",
"      Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/54\">",
"      Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/55\">",
"      Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/56\">",
"      Chase HP, Dixon B, Pearson J, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003; 143:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/57\">",
"      Hathout EH, Fujishige L, Geach J, et al. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003; 5:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/58\">",
"      Berhe T, Postellon D, Wilson B, Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. Pediatrics 2006; 117:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/59\">",
"      Alemzadeh R, Ellis JN, Holzum MK, et al. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics 2004; 114:e91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/60\">",
"      Dixon B, Peter Chase H, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005; 6:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/61\">",
"      Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005; 115:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/62\">",
"      Colino E, L&oacute;pez-Capap&eacute; M, Golmayo L, et al. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/63\">",
"      Simon D. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues. Diabetologia 2010; 53:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/64\">",
"      Fisher LK. The selection of children and adolescents for treatment with continuous subcutaneous insulin infusion (CSII). Pediatr Diabetes 2006; 7 Suppl 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/65\">",
"      Phillip M, Battelino T, Rodriguez H, et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007; 30:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/66\">",
"      Nimri R, Weintrob N, Benzaquen H, et al. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006; 117:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/67\">",
"      Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003; 143:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/68\">",
"      Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/69\">",
"      Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004; 114:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/70\">",
"      Litton J, Rice A, Friedman N, et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002; 141:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/71\">",
"      Pa��kowska E, Szypowska A, Lipka M, Sk&oacute;rka A. Sustained metabolic control and low rates of severe hypoglycaemic episodes in preschool diabetic children treated with continuous subcutaneous insulin infusion. Acta Paediatr 2007; 96:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/72\">",
"      Sulmont V, Souchon PF, Gouillard-Darnaud C, et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? J Pediatr 2010; 157:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/73\">",
"      Fox LA, Buckloh LM, Smith SD, et al. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005; 28:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/74\">",
"      Weinzimer SA, Swan KL, Sikes KA, Ahern JH. Emerging evidence for the use of insulin pump therapy in infants, toddlers, and preschool-aged children with type 1 diabetes. Pediatr Diabetes 2006; 7 Suppl 4:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/75\">",
"      Blair JC, Peak M, Gregory JW. What is the best way to deliver subcutaneous insulin to infants, children, and young people with type 1 diabetes mellitus? BMJ 2011; 343:d5221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/76\">",
"      DiMeglio LA, Pottorff TM, Boyd SR, et al. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004; 145:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/77\">",
"      Wilson DM, Buckingham BA, Kunselman EL, et al. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005; 28:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/78\">",
"      Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003; 112:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/79\">",
"      Eugster EA, Francis G, Lawson-Wilkins Drug and Therapeutics Committee. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics 2006; 118:e1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/80\">",
"      Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/81\">",
"      Pa��kowska E, Szypowska A, Lipka M, et al. Application of novel dual wave meal bolus and its impact on glycated hemoglobin A1c level in children with type 1 diabetes. Pediatr Diabetes 2009; 10:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/82\">",
"      Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/83\">",
"      Glaser NS, Iden SB, Green-Burgeson D, et al. Benefits of an insulin dosage calculation device for adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2004; 17:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/84\">",
"      McMahon SK, Airey FL, Marangou DA, et al. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabet Med 2005; 22:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/85\">",
"      Alsaleh FM, Smith FJ, Taylor KM. Experiences of children/young people and their parents, using insulin pump therapy for the management of type 1 diabetes: qualitative review. J Clin Pharm Ther 2012; 37:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/86\">",
"      Conwell LS, Pope E, Artiles AM, et al. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr 2008; 152:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/87\">",
"      Wiebe DJ, Croom A, Fortenberry KT, et al. Parental involvement buffers associations between pump duration and metabolic control among adolescents with type 1 diabetes. J Pediatr Psychol 2010; 35:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/88\">",
"      Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986; 315:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/89\">",
"      Colino E, &Aacute;lvarez M&Aacute;, Carcavilla A, et al. Insulin dose adjustment when changing from multiple daily injections to continuous subcutaneous insulin infusion in the pediatric age group. Acta Diabetol 2010; 47 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/90\">",
"      Kulkarni K, Castle G, Gregory R, et al. Nutrition Practice Guidelines for Type 1 Diabetes Mellitus positively affect dietitian practices and patient outcomes. The Diabetes Care and Education Dietetic Practice Group. J Am Diet Assoc 1998; 98:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/91\">",
"      Wise JE, Kolb EL, Sauder SE. Effect of glycemic control on growth velocity in children with IDDM. Diabetes Care 1992; 15:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/92\">",
"      Landolt MA, Vollrath M, Laimbacher J, et al. Prospective study of posttraumatic stress disorder in parents of children with newly diagnosed type 1 diabetes. J Am Acad Child Adolesc Psychiatry 2005; 44:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/93\">",
"      de Wit M, Snoek FJ. Depressive symptoms and unmet psychological needs of Dutch youth with type 1 diabetes: results of a web-survey. Pediatr Diabetes 2011; 12:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/94\">",
"      Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/95\">",
"      Orr DP, Golden MP, Myers G, Marrero DG. Characteristics of adolescents with poorly controlled diabetes referred to a tertiary care center. Diabetes Care 1983; 6:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/96\">",
"      Stewart SM, Rao U, Emslie GJ, et al. Depressive symptoms predict hospitalization for adolescents with type 1 diabetes mellitus. Pediatrics 2005; 115:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/97\">",
"      Hatherly K, Smith L, Overland J, et al. Glycemic control and type 1 diabetes: the differential impact of model of care and income. Pediatr Diabetes 2011; 12:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/98\">",
"      Carter PJ, Cutfield WS, Hofman PL, et al. Ethnicity and social deprivation independently influence metabolic control in children with type 1 diabetes. Diabetologia 2008; 51:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/99\">",
"      Schwartz DD, Cline VD, Axelrad ME, Anderson BJ. Feasibility, acceptability, and predictive validity of a psychosocial screening program for children and youth newly diagnosed with type 1 diabetes. Diabetes Care 2011; 34:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/100\">",
"      Kalyva E, Malakonaki E, Eiser C, Mamoulakis D. Health-related quality of life (HRQoL) of children with type 1 diabetes mellitus (T1DM): self and parental perceptions. Pediatr Diabetes 2011; 12:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/101\">",
"      Shorer M, David R, Schoenberg-Taz M, et al. Role of parenting style in achieving metabolic control in adolescents with type 1 diabetes. Diabetes Care 2011; 34:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/102\">",
"      Lindstr&ouml;m C, Aman J, Norberg AL. Parental burnout in relation to sociodemographic, psychosocial and personality factors as well as disease duration and glycaemic control in children with Type 1 diabetes mellitus. Acta Paediatr 2011; 100:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/103\">",
"      Vesco AT, Anderson BJ, Laffel LM, et al. Responsibility sharing between adolescents with type 1 diabetes and their caregivers: importance of adolescent perceptions on diabetes management and control. J Pediatr Psychol 2010; 35:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/9/40090/abstract/104\">",
"      Iafusco D, Galderisi A, Nocerino I, et al. Chat line for adolescents with type 1 diabetes: a useful tool to improve coping with diabetes: a 2-year follow-up study. Diabetes Technol Ther 2011; 13:551.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5817 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40090=[""].join("\n");
var outline_f39_9_40090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ongoing management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AGE-BASED CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Toddlers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preschool and early school-aged children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      School-aged children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15751005\">",
"      Transition into adult care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Age-specific goals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BLOOD GLUCOSE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fingersticks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Continuous glucose monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INSULIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11299132\">",
"      Value of an intensive regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11299231\">",
"      Types of intensive regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Multiple daily injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Insulin pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Balance of insulins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Honeymoon phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10801887\">",
"      NEWER THERAPIES FOR TYPE 1 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8539070\">",
"      Parental and caregiver involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14093656\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14093663\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14093670\">",
"      - Referrals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Special situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5817|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/55/43901\" title=\"figure 1\">",
"      Retinopathy and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/41/5789\" title=\"figure 2\">",
"      Hypoglycemia and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/32/29197\" title=\"figure 3\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/21/18781\" title=\"figure 4\">",
"      Nephropathy and control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5817|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/29/18909\" title=\"table 1\">",
"      Diabetes education checklist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/33/24091\" title=\"table 2\">",
"      Web resources diabetes child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/6/14445\" title=\"table 3\">",
"      Developmental issues diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/26/28076\" title=\"table 4\">",
"      Plasma glucose A1C goals age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/55/18300\" title=\"table 5\">",
"      Available insulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/21/35164\" title=\"table 6\">",
"      ADA lipid guideline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=related_link\">",
"      Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=related_link\">",
"      Management of smoking cessation in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/47/6899?source=related_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21606?source=related_link\">",
"      Self-management education for the child with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=related_link\">",
"      Special situations in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_9_40091="ACCP guidelines Rx of HIT";
var content_f39_9_40091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2012 ACCP recommended treatment of heparin-induced thrombocytopenia (HIT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The following non-heparin agents are recommended for use in acute HIT",
"        <strong>",
"         whether or not complicated by thrombosis",
"        </strong>",
"        : argatroban or danaparoid. Argatroban is suggested over danaparoid in those with renal insufficiency.&nbsp;(Editor's note: Lepirudin is no longer available).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In pregnant patients with HIT, the use of danaparoid is suggested over other non-heparin anticoagulants. The use of fondaparinux is suggested only if danaparoid is not available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with antibody-positive HIT who require urgent cardiac surgery, the use of bivalirudin is suggested over other non-heparin anticoagulants. In patients with antibody-positive HIT who require percutaneous coronary interventions, the use of bivalirudin or argatroban is suggested over other non-heparin anticoagulants.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin alone should",
"        <strong>",
"         not",
"        </strong>",
"        be used to treat HIT because of the risk of causing venous limb gangrene and/or skin necrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin is safe to use when it is given to a patient adequately and stably anticoagulated with a drug that reduces thrombin generation (eg, danaparoid, argatroban); it is prudent to delay use of warfarin until the platelet count is &gt;150,000/microL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LMWH should not be given to patients with HIT, whether or not complicated by thrombosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylactic platelet transfusions should not be administered for the treatment of patients with HIT who do not have active bleeding.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACCP: American College of Chest Physicians; DVT: deep venous thrombosis; LMWH: low molecular weight heparin.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Linkins LA, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians Evidence-based clinical practice guidelines. Chest 2012; 141:e495S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40091=[""].join("\n");
var outline_f39_9_40091=null;
var title_f39_9_40092="Approach to the diagnosis of NK cell deficiency";
var content_f39_9_40092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to the diagnosis of NK cell deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Evaluation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abnormal result&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identification",
"       </td>",
"       <td>",
"        Lymphocyte subset analysis",
"       </td>",
"       <td>",
"        Fluorescence activated cell sorting (FACS)",
"       </td>",
"       <td colspan=\"1\">",
"        Absent or decreased",
"       </td>",
"       <td>",
"        Separate CD56 and CD16 evaluations&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ex Vivo function",
"       </td>",
"       <td>",
"        NK cytotoxicity ADCC",
"       </td>",
"       <td>",
"        Cytotoxicity assay",
"       </td>",
"       <td colspan=\"1\">",
"        Absent or decreased&Delta;",
"       </td>",
"       <td>",
"        Always ship samples with an unrelated control&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        In Vitro responsiveness",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cytokine induced cytotoxicity and cytokine production",
"       </td>",
"       <td>",
"        Cytotoxicity assay",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Absent or decreased",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Stimulants include IL-2, IL-12, and IFN-&alpha;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracellular FACS*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenotype",
"       </td>",
"       <td>",
"        NK cell subset analysis",
"       </td>",
"       <td>",
"        FACS",
"       </td>",
"       <td>",
"        Missing/ decreased activation receptor or increased inhibitory receptor",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specific receptor function",
"       </td>",
"       <td>",
"        Redirected lysis and other antibody or ligand directed assays",
"       </td>",
"       <td>",
"        Cytotoxicity assay, granule release, Ca++ flux and others",
"       </td>",
"       <td colspan=\"1\">",
"        Decreased activity after specific receptor ligation.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A major cytokine produced by NK cells that is presumably of biologic relevance is IFN-&Gamma;. This factor can be measured intracellularly in NK cells most easily after short-term exposure to mitogen.",
"     <br>",
"      &bull; Although it is difficult to interpret a decreased result, values that are persistently lower than the reference range for the laboratory experienced in the investigation may be of significance and worthy of further study.",
"      <br>",
"       &Delta; Decreased ex vivo NK cell function in total PBMC preparations may be due to decreased NK cell numbers and thus may be a defect of NK cell production or survival and not that particular function. If the patient possesses a small population of NK cells this issue can be addressed using purified or enriched NK cells.",
"       <br>",
"        &loz; Many clinical laboratories use a reagent to identify NK cells that contains anti-CD3-FITC as well as both anti-CD56-PE and anti-CD16-PE. Although this reagent will identify NK cells it will overlook all patients with an alteration of CD16. In suspected cases both CD16 and CD56 should be evaluated separately. Anti-CD16 clone 3G8 will recognize variant receptors while clone B73.1 will not. Both reagents are commercially available.",
"        <br>",
"         &sect; Extreme conditions during shipping can affect biological activity and thus a shipping control is necessary. It is important that the control be unrelated, as some NK deficiencies are present in families.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40092=[""].join("\n");
var outline_f39_9_40092=null;
var title_f39_9_40093="Metabolic syndrome race";
var content_f39_9_40093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Prevalence of NCEP ATP III metabolic syndrome among subjects in the NHANES III survey by race/ethnicity and sex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40093=[""].join("\n");
var outline_f39_9_40093=null;
var title_f39_9_40094="Vitamin K pathway";
var content_f39_9_40094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Biosynthetic pathway for vitamin K-dependent production of gamma-carboxyglutamic acid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It has been hypothesized that a free cysteine residue in the carboxylase converts vitamin KH2 into a \"strong base\" of sufficient basicity to abstract a hydrogen from the gamma-carbon of glutamic acid (shown in red). However, the role of a free cysteine in the carboxylation reaction is uncertain. Subsequently, CO2 is added to the gamma-carbon of glutamic acid to form gamma-carboxyglutamic acid. The activated vitamin K species collapses into vitamin K epoxide and is recycled back to vitamin KH2, following the action of two vitamin K reductases, one of which is inhibited by warfarin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data redrawn from Furie, B, Bouchard, BA, Furie, BC. Blood 1999;93:1798.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40094=[""].join("\n");
var outline_f39_9_40094=null;
var title_f39_9_40095="RB ILD CT I";
var content_f39_9_40095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory bronchiolitis-associated interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan (5 mm thick section) in a 35-year-old woman with heavy smoking history and progressive dyspnea with exertion shows extensive ground-glass opacities. The plain chest film was normal. The diagnosis was confirmed by open lung biopsy. Symptoms improved following smoking cessation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_9_40095=[""].join("\n");
var outline_f39_9_40095=null;
